US20040024354A1 - Transfer device and method for transferring a pharmaceutical component between a vial and a syringe - Google Patents
Transfer device and method for transferring a pharmaceutical component between a vial and a syringe Download PDFInfo
- Publication number
- US20040024354A1 US20040024354A1 US10/367,607 US36760703A US2004024354A1 US 20040024354 A1 US20040024354 A1 US 20040024354A1 US 36760703 A US36760703 A US 36760703A US 2004024354 A1 US2004024354 A1 US 2004024354A1
- Authority
- US
- United States
- Prior art keywords
- syringe
- vial
- needle
- assembly
- tubular connector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000012546 transfer Methods 0.000 title claims abstract description 42
- 239000005426 pharmaceutical component Substances 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 16
- 230000008878 coupling Effects 0.000 claims description 27
- 238000010168 coupling process Methods 0.000 claims description 27
- 238000005859 coupling reaction Methods 0.000 claims description 27
- 239000012530 fluid Substances 0.000 claims description 26
- 230000000717 retained effect Effects 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 3
- 239000000306 component Substances 0.000 description 54
- 238000001994 activation Methods 0.000 description 25
- 230000004913 activation Effects 0.000 description 23
- 239000007788 liquid Substances 0.000 description 23
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 238000003780 insertion Methods 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- 229940071643 prefilled syringe Drugs 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000004891 communication Methods 0.000 description 7
- 239000000825 pharmaceutical preparation Substances 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000013536 elastomeric material Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2096—Combination of a vial and a syringe for transferring or mixing their contents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2089—Containers or vials which are to be joined to each other in order to mix their contents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/225—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1475—Inlet or outlet ports
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
- A61J1/2006—Piercing means
- A61J1/201—Piercing means having one piercing end
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
- A61J1/2006—Piercing means
- A61J1/2013—Piercing means having two piercing ends
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
- A61J1/2048—Connecting means
- A61J1/2051—Connecting means having tap means, e.g. tap means activated by sliding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
- A61J1/2048—Connecting means
- A61J1/2058—Connecting means having multiple connecting ports
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
- A61J1/2048—Connecting means
- A61J1/2065—Connecting means having aligning and guiding means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
- A61J1/2079—Filtering means
- A61J1/2086—Filtering means for fluid filtration
Definitions
- the present invention is directed to a syringe adapter, and more particularly to a device that allows a user to reconstitute medicine in sealed vials.
- compositions must be distributed as two or more separate components which can only be combined shortly before administration of the preparation, usually because the combined preparation is subject to rapid deterioration or otherwise unstable, and the components are only stable when stored separately.
- at least one component of such a preparation is a liquid which acts as a solvent, diluent or carrier for the other component.
- U.S. Pat. No. 3,872,867 utilizes a tubular assembly incorporating a double ended cannula, into which two pharmaceutical vials are pressed in order to combine components in the two vials.
- the system requires that one of the vials is under vacuum at pressure, and merely results in a vial containing the combined product, which must still be transferred to a syringe for administration.
- U.S. Pat. No. 3,563,373 discloses an arrangement utilizing two cartridges in tandem for packaging a two component pharmaceutical, utilizing an intermediate assembly incorporating a double ended needle, which penetrates the piston of one cartridge and neck stopper of the other.
- the arrangement cannot utilize a standard pharmaceutical vial.
- U.S. Pat. No. 4,583,971 discloses apparatus for transferring liquid through a cannula from a flexible container to dissolve a pharmaceutical, and returning the solution to the flexible container.
- the system is dependent upon manipulation of a tangible closure through the flexible container and could not be used to transfer liquid from a syringe to a pharmaceutical vial and back again.
- U.S. Pat. No. 5,171,214 discloses a combination of a vial assembly, a syringe assembly, and an adapter for attaching the vial assembly to the syringe assembly so that a liquid constituent may be transferred from the syringe to the vial and the admixed compounds returned to the syringe.
- a special vial and special syringe are required, and indeed the system is predicated upon the use of a proprietary vial assembly.
- An object of the present invention is to provide a delivery system for two component pharmaceuticals which is economical to manufacture, easy to manipulate, and can minimize regulatory burdens.
- an activation assembly for preparing a prefilled syringe from separately prepackaged components of a multicomponent pharmaceutical preparation, the assembly comprising a two part tubular body; the body defining in a first part a first cylindrical recess at one end of a diameter to receive, as a sliding fit, a discharge end of cylindrical body of a protosyringe at which end is located a closure, broachable on activation of the protosyringe, the recess also receiving a substantial portion of the cylindrical body of the protosyringe, which contains a first, liquid component of the pharmaceutical preparation and which is provided at its opposite end with a piston displaceable longitudinally of the cylindrical body and forming a hermetic seal therewith; a second cylindrical recess defined in the other end of the tubular body by a second detachable part to receive a cap securing a penetrable closure at the neck of the pharmaceutical vial containing a second component of the pharmaceutical preparation; the tubular
- a ‘protosyringe’ is an assembly intended to form the basis of a prefilled syringe but requiring the addition of components to form a complete syringe. At minimum, it includes a cylindrical body containing at least a component of a pharmaceutical product, the body being closed at one end by a broachable closure and being at an opposite end with a piston connected to or provided with means for connection to an activating plunger so that the latter may be used to displace the contents of the body.
- Protosyringes include bottomless vials as described in my U.S. Pat. No.
- an ‘overcap’ is a cap adapted to be lodged on the cap of a protosyringe and providing means for supporting a needle or other instrumentality through which contents of a syringe formed from the protosyringe may be discharged.
- a complete prefilled syringe itself may be used as a protosyringe if it has a luer connection closed by a cap of penetrable material over which an overcap may be received.
- the invention also extends to the combination of such an assembly with a protosyringe and/or pharmaceutical vials already engaged in their associated cylindrical recesses. If the protosyringe is already engaged in the first cylindrical recess, its free end may be covered by a removable cap to prevent accidental projection into the cylindrical bottom resulting in premature actuation of the assembly.
- the associated sealing member in the assembly is in resilient contact with the penetrable closure of the vial in areas concentric with the cannula so as to help maintain sterility of areas of the sealing members and closures intended to be penetrated by the cannula.
- the hub assembly and a modified overcap may also be utilized in conjunction with a protosyringe or pharmaceutical vial to provide alternative delivery systems for pharmaceuticals contained in the protosyringe or vial.
- FIG. 1 is an exploded view of the components of an assembly according to the invention, including both a protosyringe, in this case a bottomless vial, and a pharmaceutical vial;
- FIG. 2 illustrates an assembly according to the invention, including a bottomless vial, as it might be shipped;
- FIG. 3 illustrates a similar assembly, but further including a pharmaceutical vial, ready for activation
- FIG. 4 illustrates in part sectional view components of an assembly according to FIG. 3, but with upper components removed for clarity;
- FIG. 5 is a similar view to FIG. 4, but showing the illustrated components in the relationship which they assume after activation of the assembly in order to prepare a completed prefilled syringe;
- FIG. 6 is a view of the assembly corresponding to FIG. 3, after activation;
- FIG. 7 is a view of the assembly after the plunger has been pressed upwardly to transfer liquid from the bottomless vial to the pharmaceutical vial;
- FIG. 8 is a view showing a mixing step
- FIG. 9 shows upper portions of the assembly being removed, leaving a syringe ready for application of a needle or other discharge means
- FIG. 10 shows a partially exploded view of a modified embodiment of delivery system utilizing a different form of protosyringe
- FIGS. 11 and 12 are fragmentary sectional views of an alternative form of syringe socket and associated parts which permit elements of the delivery system to be used in further embodiments of delivery system in conjunction with prefilled protosyringes or pharmaceutical vials;
- FIG. 13 shows in section a cap which may be applied to a luer on a hub portion of the embodiment of FIGS. 11 and 12 to enable the hub to be driven from the position to FIG. 11 to that of FIG. 12 to activate a prefilled protosyringe;
- FIG. 14 shows in an exploded view parts of an alternative activation system for use with the embodiment of FIGS. 11 and 12 so as to activate a syringe or vial for use in conjunction with a standard flexible mini-bag;
- FIG. 15 shows an assembled syringe ready for activation
- FIG. 16 shows an activated syringe applied to a mini-bag
- FIG. 17 is an exploded view illustrating components of a presently preferred modification of the embodiment of FIGS. 1 - 9 ;
- FIG. 18 shows the parts shown in FIG. 17 assembled ready for use, less the plunger
- FIGS. 19 and 20 illustrate a presently preferred modification of the embodiment of FIGS. 11 and 12;
- FIG. 21 illustrates the assembled components of a further embodiment of assembly according to the invention.
- FIG. 22 is an exploded view of components of a hub assembly used in the embodiment of FIG. 21;
- FIG. 23 illustrates a modification of the embodiment of FIG. 18, showing how the assembly of the invention may be used to activate pharmaceuticals having more than two components;
- FIG. 24 illustrates an assembly in accordance with a further embodiment of the invention
- FIG. 25 is a flow diagram illustrating the preparation of assemblies in accordance with the embodiment of FIGS. 17 and 18.
- FIGS. 26 and 27 are exploded and assembled views of a further embodiment of the invention.
- FIG. 28 is an exemplary illustration of a pharmaceutical delivery system including a pharmaceutical transfer assembly in a retracted or “unactivated” postion according to an embodiment of the invention.
- FIG. 28 a is a variation of the embodiment of FIG. 28.
- FIG. 28 b is a variation of the embodiment of FIG. 28 a showing a fully assembled device.
- FIGS. 29 and 30 illustrate successive stages in deployment of the pharmaceutical delivery system of FIG. 28 for transfer of a pharmaceutical component between a vial and a syringe.
- FIGS. 29 a and 30 a illustrate successive stages in deployment of the pharmaceutical delivery system of FIG. 28 a for transfer of a pharmaceutical component between a vial and a syringe.
- FIG. 30 b is a plan view taken along line A-A of the transfer device of FIG. 30A.
- FIG. 31 is an exemplary illustration of a pharmaceutical delivery system including a pharmaceutical transfer assembly in a retracted or “unactivated” postion according to another embodiment of the invention.
- FIG. 31 a is a variation of the embodiment of FIG. 31.
- FIG. 31 b is a variation of the embodiment of FIG. 31 a showing a fully assembled device.
- FIGS. 32 and 33 illustrate successive stages in deployment of the pharmaceutical delivery system of FIG. 31 for transfer of a pharmaceutical component between a vial and a syringe.
- FIGS. 32 a and 33 a illustrate successive stages in deployment of the pharmaceutical delivery system of FIG. 31 a for transfer of a pharmaceutical component from a vial to a syringe.
- FIG. 34 is an exemplary illustration of a pharmaceutical delivery system including a pharmaceutical transfer assembly in a retracted or “unactivated” postion according to yet another embodiment of the invention.
- FIG. 34 a is a variation of the embodiment of FIG. 34 showing a fully assembled device.
- FIGS. 35 and 36 illustrate successive stages in deployment of the pharmaceutical delivery system of FIG. 34 for transfer of a pharmaceutical component between a vial and a syringe.
- FIG. 37 is an exemplary illustration of a pharmaceutical delivery system including a pharmaceutical transfer assembly in a retracted or “unactivated” postion according to yet another embodiment of the invention.
- FIG. 37A is a perspective view of a portion of the transfer assembly shown in FIG. 37.
- FIGS. 1 to 3 the parts are shown of an assembly for preparing a syringe containing a pharmaceutical preparation, components A and B of which are contained respectively in a pharmaceutical vial 2 and a protosyringe in the form of a bottomless vial 4 consisting of a cylindrical body 6 , open at one end and provided with a neck 8 at its other end, the neck being closed by an elastomeric closure 10 secured in place by a metal cap 12 crimped over the neck.
- a piston 14 is lodged in the open end of the body, the piston being provided with means 16 by which a detachable plunger 18 may be secured to the piston.
- the plunger will normally be shipped detached from the piston, both to reduce the overall length of the assembly, and to permit a removable cap 20 to be applied over a projecting end of the bottomless vial 4 as shown in FIG. 2 so as to prevent inadvertent premature activation of the assembly.
- At least one of the components A and B is liquid; usually it will be convenient to locate a liquid component in the bottomless vial but it would be possible to locate a solid component in the bottomless vial provided that the latter also contains an air or gas volume sufficient to displace liquid contents of the vial 2 .
- a typical two component pharmaceutical for administration via a syringe comprises an active ingredient and a liquid solvent, diluent or carrier (hereinafter collectively referred to as diluent for convenience) which in the majority of cases will be one of only a few different types (most usually distilled water), it will usually be advantageous to place the active component in the vial 2 ; this is because in many, if not most cases, a suitable vial package of the active ingredient will already be certified by regulatory cylindrical recess 31 into which may be slid the body 6 of the bottomless vial 4 , although not initially to the full extent permitted by the depth of the recess.
- the end portion 26 of the syringe socket includes a guide 52 with detents 53 for controlling longitudinal movement of a hub 34 having gapped longitudinal ribs 33 .
- the hub is formed at a front end with a liquid delivery conduit through a standard luer as utilized in the industry for coupling needles, or other delivery instrumentalities forming liquid delivery conduit extensions, to syringes and other sources of liquid pharmaceuticals.
- a luer comprises an internally threaded socket 36 for locking a needle in place, and a tapered central spigot 38 for establishing a seal with a complementary socket on the needle.
- a hollow transfer needle 40 has a socket 41 lodged on the central spigot, but is not provided with threads to engage those of the socket 36 , so the needle 40 may be pulled from the spigot 38 .
- a tapered shoulder 42 is formed on the transfer needle 40 .
- the hub 34 has a hollow needle or cannula 44 projecting from its end opposite the spigot 38 and in communication with a central passage in the spigot.
- a flexible needle sheath or shield 46 of thin rubber covers the needle 44 , having a portion 48 engaging a socket in the end of the hub 34 , and a flattened end 50 over the free end of the needle.
- the end portion 26 of the syringe socket also contains an extension of the cylindrical recess 31 dimensioned to provide an overcap which is a press fit over the cap 12 of the bottomless vial 4 .
- the vial coupling 22 has a passage extending from recess 30 which receives vial 2 to its internally threaded end, the passage being closed by a rubber stopper or shield 54 . Between the rubber stopper and the internally threaded end of coupling 22 , passage is formed internally with resilient pawls 56 which will detain the shoulder 42 of the needle 40 when the latter is pressed past the pawls.
- the assembly just described may be shipped on its own with neither vial installed, in which case a removable cover (not shown) will be required to cover the cylindrical recess in the coupling 22 to maintain sterility, or with one or both vials installed (see FIGS. 2 and 3).
- a vial 2 any removable central portion of a cap 60 covering a penetrable closure 58 of the vial is flipped off, so that the penetrable closure may contact a rib 64 on the stopper 54 to enclose an axial sterile zone of the two rubber parts 58 and 54 .
- an axial zone of the closure 10 similarly exposed, contacts the end 50 of the needle sheath 46 to provide protected zones on the contacting rubber parts.
- the assembly is inverted and plunger 18 is activated to project the liquid content B from the bottomless vial into the pharmaceutical vial, (see FIG. 7), the assembly then being swilled as shown in FIG. 8 to dissolve, mix or suspend the contents of the vial 2 in the liquid, which is then aspirated back into the bottomless vial by withdrawing the plunger to reach a condition similar to that of FIG. 6, except that component A is now incorporated into component B to leave a product C in the bottomless vial.
- the vial 22 is now unscrewed from the syringe socket 24 and withdrawn, taking with it the transfer needle 40 which is pulled off the spigot 38 by the pawls 56 , thus leaving the luer of hub 34 ready to receive a needle or other fluid connection instrumentality, and providing a completed ready to use syringe, filled with the two component pharmaceutical (see FIG. 9).
- the hub 34 is retained on the cap 12 of the bottomless vial by the syringe socket 24 , with the needle providing a passage between the body 6 and the luer 36 , 38 .
- the step of FIG. 7 may be performed without inversion, with reciprocation of the syringe plunger being used to force air or gas from the vial 4 to the vial 2 , and liquid from the vial 2 to the vial 4 .
- FIGS. 17 and 18 A presently preferred modification of the assembly described above is shown in FIGS. 17 and 18, in which the same reference numerals are used to designate similar parts, and only the differences are described.
- the flange 35 of the hub 34 is extended to form the overcap, and the portion 26 of the syringe socket 24 acts to receive the forward portion of this overcap when the syringe body 6 is forced forward against and into the overcap during activation of the syringe.
- this rearrangement facilitates assembly.
- the cap 20 is replaced by a driver in the form of a tubular cylindrical element 21 , which snaps into the opening of the syringe socket 24 as shown in FIG.
- the element 21 has a bottom aperture to accommodate the plunger 18 .
- the stopper 54 is replaced by a flexible sheath 54 similar to the shield 46 , since this is found to simplify assembly and provides complete coverage of the needle 40 .
- the plunger 18 in the embodiment of FIGS. 17 and 18 is provided with ribs 18 at its distal end. This facilitates an alternative mode of activation of the assembly in which the plunger 18 is assembled to the piston 14 prior to activation, and activation is achieved by pressure on the plunger. This initially drives the hub forward so that the cannula 40 penetrates the closure of he vial 2 , then drives the cap 12 into the overcap 35 to penetrate the closure of the protosyringe so that the contents of the latter may be delivered into the vial.
- the ribs 18 a abut the periphery of the opening in the bottom of the driver 21 as the plunger nears the end of its stroke, and presses forward the driver so that it snaps into the sleeve 24 , thus signalling the completion of activation.
- the needle 40 could be permanently secured to the hub 34 , and the pawls in the vial omitted. Such an arrangement does not provide the user with any choice as to the needle to be used on the finished syringe, and needle length may be severely limited by the need to avoid excess needle extent to the vial 2 , which would make it difficult to aspirate its contents.
- the bottomless vial 4 may be replaced by other forms of protosyringe such as cartridges, or by a prefilled syringe provided with an elastomeric closure covering a luer connection, the front end of the syringe accepting an overcap providing such a needle connection and acting to retain the hub.
- a prefilled syringe provided with an elastomeric closure covering a luer connection
- the front end of the syringe accepting an overcap providing such a needle connection and acting to retain the hub.
- a protosyringe which is a conventional prefilled syringe having a conventional luer nozzle 101 protected by a protective rubber sealing cap 100 over a front end of the syringe body, and the syringe socket 24 is modified in shape to receive the body 6 of the syringe, with longitudinal internal ribs 102 to grip the syringe body.
- a cap 20 prevents the syringe body from being driven fully into the syringe socket 24 until activation is required, and the end 50 of the shield 46 rests against the cap 100 to help maintain sterility of the zones to be penetrated by the needle 44 .
- a known form of diluent vial comprises a body 6 in the form of a glass tube with a piston at both ends.
- the piston at one end is similar to the piston 14 with an extension similar to the extension 16 .
- the piston at the other end fulfils the function of the neck 8 , stopper 10 and cap 12 of the bottomless vial shown in FIG. 1.
- this other end of the vial is inserted into an open end of a sleeve which at its other end supports a luer or needle externally and an axial hollow pin projecting internally.
- the piston at the other end of the vial has an axial passage, through the piston and an outward extension of the piston, closed at its outer end by a bung which is displaced by the hollow pin on insertion of the vial into the sleeve, thus establishing communication between the needle or luer and the interior of the vial.
- Protosyringe from a vial into a syringe is completed by applying a plunger to the piston at the first end.
- This type of protosyringe can be substituted in the present invention for that shown in FIG. 1 or FIG. 17.
- the overcap 16 or 35 will be driven into the extension of the piston at said other end of the vial so that the needle 44 penetrates the sheath 46 and displaces the bung.
- the bung may be replaced by an integral septum in the passage of the piston which is penetrated by the needle 44 .
- the syringe socket itself may be made detachable from the completed syringe except for the overcap, or may be truncated in length as shown in FIGS. 11 and 12. It will be seen that the syringe socket 24 is shortened and reduced in diameter to receive the cap 12 of a bottomless vial, the syringe socket being pushed down over the cap 12 to engage the shoulder of the syringe body 6 .
- the hub 34 On activation of the syringe the hub 34 is driven downwardly relative to the end portion 26 of the socket 24 from the position shown in FIG. 11 to the position shown in FIG. 12. In the position shown in FIG. 11, the end 50 of the rubber shield 46 rests against the closure 10 so as to provide a protected contact zone, which is penetrated by the needle 44 on the hub 34 as the hub is driven downwardly through the guide 52 until a flange 35 on the bottom of the hub 34 contacts the closure 10 . At this point the needle 44 establishes communication with the interior of the body 6 of the protosyringe.
- FIG. 21 shows how the arrangement of FIGS. 11 and 12 (or FIGS. 19 and 20 considered below) may be used in an arrangement in which the assembly is activated by insertion of the vial 2 .
- the component 42 is lengthened and modified so that it, the penetrable shield 54 on the cannula 40 , and the cannula 40 itself, project into the vial socket 32 .
- the shield 54 On insertion of the vial 2 , the shield 54 is pressed into a recess in the arrangement 42 so that it is penetrated by the cannula, which also penetrates the closure of the vial 2 , and the vial closure presses on the component 42 so as to drive the cannula 44 through its sheath or shield and the penetrable closure of the protosyringe.
- FIGS. 19 and 20 If the modification of FIGS. 19 and 20 is used, with a hub 34 modified as shown in FIG. 22 so that the flange 35 provides the overcap, this driving action also drives the overcap 35 onto the cap of the protosyringe. If the arrangement of FIGS. 11 and 12 is used, the cap of the protosyringe is already lodged in the overcap.
- FIG. 13 illustrates an alternative means of driving the hub 34 .
- the luer spigot 38 of the hub 34 is covered by a conventional moulded cover 104 , shown in section in FIG. 13, screwed into the socket 36 and providing a convenient driver for the hub which can be unscrewed and discarded preparatory to fitting a needle to the luer of the hub.
- FIGS. 14 and 15 illustrate an alternative driver arrangement, making use of a known type of adapter used to couple syringes to flexible mini-bags so that the contents of the syringe may be discharged into the bag and mixed with the contents of the latter.
- the adapter 106 consists of a tube 108 which has an internally threaded socket 118 at one end for screwing in the present case on to complementary external threads on the portion 26 of a syringe socket 24 , and slots 110 at the other end to engage lugs on a nipple of the bag so that the nipple is guided into the adapter concentrically aligned with a needle 112 fitted to the spigot 38 of the hub 34 .
- a cap 114 covers the slotted end of the tube 108 , and has a concentric internal tubular extension 116 that sheathes the needle 112 , and extends the socket 36 of the hub 34 when the latter is in the position shown in FIG. 11, with the tube 108 extending only part way into the cap 114 . Pushing further on the cap will force the hub 34 from the position shown in FIG. 11 to the position shown in FIG. 12, thus activating the syringe. The cap 114 may then be removed, and the syringe applied to a mini-bag as shown in FIG. 16. Alternatively the tube 10 may also be removed providing a ready to use syringe.
- FIGS. 11, 12, 14 and 15 may also be used to activate a regular pharmaceutical vial so that its contents may be mixed with those of a mini-bag or other flexible bag. Liquid from the flexible bag may be caused to enter the activated vial through the needle, and the admixed contents of the vial then allowed to run back into the bag through the needle by suitable manipulation of the bag and the attached activated vial.
- FIGS. 11 and 12 may also be modified as shown in FIGS. 19 and 20 by extending the flange 35 of the hub 34 to form the overcap (see also FIG. 22).
- the reduced diameter portion of the syringe socket is extended downward as at 27 to form a shoulder limiting insertion of the protosyringe.
- FIG. 23 shows a modification of the embodiment of FIGS. 17 and 18 to allow preparation of a three component pharmaceutical.
- the vial socket 22 is bifurcated, as is the component 42 , so as to provide two vial sockets 30 , and two needles which are not seen since they are covered by sheaths 54 .
- the closures of the vials will be penetrated simultaneously, enabling liquid from the protosyringe body 6 to enter both vials 2 and dissolve or suspend their contents.
- latch members 56 engage the component 42 to retain it, as in previous embodiments.
- a further vial socket 30 and a further branch of the component 42 may be provided for each additional component to be handled.
- the principles of the invention may also be utilized with protosyringes in the form of a shell vial (or as shown, the functional equivalent of a shell vial produced by reversing a bottomless vial 206 as described in U.S. Pat. No. 5,364,369A and applying a driver cap 220 to its cap end).
- shell vials are normally formed into a completed syringe by screwing a threaded extension 216 of a piston 214 into a free end of a plunger stem within a concentric syringe shell connected to the other end of the plunger.
- a double ended needle extends axially of the plunger stem and out of its other end.
- a syringe socket 224 provides the shell, and the hub assembly utilized in the embodiment of FIGS. 1 - 10 , modified as shown in FIGS. 17 and 18, is further modified by providing an elongated cannula 244 surrounded by a concentric plunger stem 218 positioned on the cannula by passing through a flange 245 and entering the overcap 35 .
- the length of the cannula 244 is such that it ends short of a penetrable septum (not shown) within the piston 21 with the components in the unactivated state shown in FIG. 24, with the piston extension 216 screwed into a threaded socket at the bottom of stem 218 .
- the assembly is activated by driving the shell vial upwardly so that a reduced diameter portion 219 of the stem 228 enters the overcap 35 , permitting the cannula 244 to perforate the septum in the piston. Further upward movement causes the cannula supported at the upper end of the hub to penetrate the sheath 64 and the penetrable closure of the vial 2 , whereafter activation can proceed as previously described save that the shell vial 206 is manipulated in place of a conventional plunger.
- FIG. 25 there is shown a flow diagram of the preparation of an assembly in accordance with the invention, specifically the embodiment of FIGS. 17 and 18.
- the parts 34 , 35 , 42 , 46 and 64 are assembled to form the hub assembly 300 , which is then sterilized by gamma radiation (step 320 ).
- the parts 6 , 12 , 14 , 16 are assembled and filled to provide a protosyringe 304 to the cap of which the overcap 35 is applied, but not far enough for the cannula within the overcap 35 to penetrate the shield or sheath 46 , to provide subassembly 306 , which then passes through an inspection station 316 .
- parts 21 , 22 and 24 are assembled to provide a subassembly 302 and, together with the plunger 18 , sterilized by gamma radiation at 322 .
- the assembly 306 of protosyringe and hub assembly is inserted into the assembly 302 under a laminar flow hood to provide the assembly 308 , whereafter, in the same environment, a vial 2 , from which any protective metal disc on the cap has been flipped off, is inserted into the vial socket of the assembly 308 , which corresponds exactly to that of FIG. 18.
- the contacting surface of the penetrable closure 58 (see FIG.
- the vial 2 and the surface 50 of the shield 64 are sterilized by a high intensity ultraviolet flash or an antiseptic spray 318 during this step, whereafter the resulting assembly 310 together with the plunger 18 is sealed into a plastic tray 312 .
- the tray is vacuum formed with a recess shaped to correspond to the profile of the assembly 310 .
- this recess snugly embraces the narrower portion of the actuator 21 to avoid any possibility of inadvertent activation prior to use occasioned by shock or rough handling.
- the protosyringe 304 like the vial might be preproduced and terminally sterilized, and assembled to the hub assembly to produce the assembly 306 in a similar manner to combination of assemblies 302 and 308 .
- activation of the protosyringe involves penetration of the closure of the protosyringe by a second cannula on the hub, but the invention is also applicable to protosyringes activated by other means.
- U.S. Pat. No. 3,967,759 (Baldwin) there is disclosed a protosyringe in which the closure at the capped end of the body of the protosyringe is a plug lodged in an end of a tubular body, which closure is breached by ejection of the plug into a hollow interior of the cap such that the contents of the syringe may bypass the plug within the cap.
- Such a protosryinge is activated by application of fluid pressure to the plug by the application in turn of longitudinal pressure to the piston of the protosyringe by a plunger, and thus the second cannula and its associated sheath is not required.
- FIGS. 26 and 27 This arrangement is exemplified in FIGS. 26 and 27, in which the same reference numerals are used to identify the same parts as in FIGS. 1 - 8 or 17 , and only the points of difference will be discussed in detail.
- the components shown in the left hand portions of FIG. 26, with the exception of a filter 400 are essentially identical to the corresponding components of the embodiment of FIGS. 17 and 18, but the protosyringe shown in the right hand of FIG. 26 is essentially similar to that described with reference to FIGS. 1 - 4 of U.S. Pat. No.
- the plug 10 corresponds to the plug 51 of the Baldwin patent, and may be formed with ribs similar to the ribs 53 of Baldwin or other means to ensure that, once the plug moves forward from the body 6 into the cap 12 , the seal formed by the plug remains broached, and liquid can bypass the plug.
- displaceable plugs generally similar to that disclosed in the Baldwin patent but differing in detail in the means used to ensure that the plug remains bypassed once broached, and these could also be utilized.
- An adaptor 400 containing a filter may be provided secured to the connector 41 on the cannula 40 , the adaptor being a press fit on the luer 38 , such that when the cannula 40 is captured by the detents 56 and the portion 22 is removed, the adaptor 400 discarded with the cannula 40 and the portion 22 .
- This enables a filter, incorporated in the adaptor 400 , to be utilized during transfer of liquid between the vial 2 and the protosyringe during an activation process, so that any particulate may be removed from the reconstituted pharmaceutical as it is drawn back into the protosyringe.
- the activation process is generally quite similar to that previously described. Referring to FIG. 27, pressing down on the activation cap 21 causes the latter to move into the open end of the socket 24 and press the piston retainer 402 at the rear end of the body 6 so as to move the cap 12 into the overcap 26 . This moves the hub assembly formed by the luer 34 , adaptor 400 and cannula 40 upwardly within the sleeve 22 until the cannula 40 pierces the closure of the vial 2 .
- the plunger 18 can then be attached to the piston 14 , and on applying pressure to the plunger, the plug 10 is moved forward to broach the closure of the protosyringe at its capped end, allowing the contents of the syringe to be discharged through the cannula 40 into the vial 2 .
- the dissolved pharmaceutical is withdrawn back into the protosyringe through the cannula 40 and the filter in adaptor 400 , and the filled syringe is removed as shown in FIG. 9, leaving behind the cannula 40 and the adaptor 400 containing the filter, and presenting the luer 34 for attachment of a hypodermic needle or other injection instrumentality.
- the portion of cap 12 beyond the body 6 has a smaller rather than larger internal diameter than the body 6 , and the plug 10 is initially lodged in that portion of the cap 12 .
- the 44 of the FIG. I or 17 embodiment is replaced by an activator rod, and the hub is made axially movable relative to the protosyringe as in the previous embodiments, so that on actuation of the syringe, the rod is projected against the plug 10 in the cap 12 and dislodges it into the body 6 to broach the seal of the protosyringe.
- FIGS. 28 - 30 illustrate an embodiment of a syringe device similar to that of FIGS. 26 and 27, with like reference numerals used to indicate like parts, wherein vial coupler 22 includes a first open end having a vial socket 32 for receiving the cap end of vial 2 having a penetrable closure 4 , and a second open end for receiving a mounting end of syringe 66 .
- Vial coupler 22 further includes a series of ribs 22 c formed on inner wall 22 a and extending longitudinally down the length of the vial coupler.
- Adaptor 400 comprises annular retaining member 401 appropriately sized for retention within a portion 23 via detents 26 , 28 formed on ribs 22 c .
- the detents operate to impede longitudinal movement of the adapter so as to confine the adapter to portion 23 when the device is in the retracted position or “unactivated” state, as shown in FIG. 28.
- This in turn maintains the position of the hub and needle assembly comprising hub shoulder 42 and socket connector 41 , with hollow needle or cannula 40 retained within the shoulder portion.
- the cannula is staked within the hub shoulder providing an enlarged blunt mounting end received by adapter 400 .
- retaining member 401 also operates as a filter for trapping particulate matter traversing the passageway between syringe 66 and vial 2 when the device is in the advanced position or “activated” state (i.e.
- a series of ribs 401 a formed about the circumference of retaining member 401 are adapted to slidably interlock with corresponding longitudinal ribs 22 c (best seen in the embodiment shown in FIG. 30 b ) extending down vial coupler 22 to prevent rotation of retaining member 401 and the needle and hub assembly.
- Luer 38 is formed on syringe 66 for coupling adapter 400 at externally threaded open receiving end 404 via cooperating internal threads formed on the syringe luer portion.
- Adapter 400 further includes open receiving end 406 which is secured to socket connector 41 for establishing the passageway through the hub and needle arrangement.
- Other well known means for securing adapter 400 to connector 41 of the hub and needle arrangement may be employed, including for example, press fit or snap fit, adhesive coupling and the like.
- Syringe 66 further includes socket 24 capable of carrying a transferable material such as a fluid for transfer between the syringe and the vial 2 through vial coupler 22 .
- the method for deploying the pharmaceutical delivery system comprises coupling luer 38 of syringe 66 to adapter 400 ; advancing the syringe 66 and thus the adapter 400 (and hub and needle assembly) longitudinally within the vial coupler 22 from the retracted position to the advanced position whereby the hub shoulder portion moves past the resilient pawls 56 during advancement and the tip 40 a of cannula 40 penetrates the penetrable closure on vial 2 to create fluid communication between the vial and the syringe.
- a plunger rod (not shown) is inserted into flange end 68 in the direction illustrated by arrow A (FIG. 29) to project the contents of the material in socket 24 into pharmaceutical vial 2 .
- the assembly is then swilled to dissolve, mix or suspend the contents of vial 2 with that of the pharmaceutical component from the syringe.
- Withdrawing the plunger aspirates the contents of the vial 2 into the syringe 66 , and the syringe is detached from the adapter 400 (and hub and needle assembly) by unscrewing luer 38 from adapter end 404 to provide a syringe without needle but otherwise ready for use (see FIG. 30).
- vial 2 may contain a pharmaceutical component (e.g. a fluid or powder) and the prefilled syringe may contain another pharmaceutical component (e.g. a fluid or powder).
- a pharmaceutical component e.g. a fluid or powder
- the prefilled syringe may contain another pharmaceutical component (e.g. a fluid or powder).
- the fluid contents of the syringe are injected into the vial (e.g. by depression of a plunger); the components are then mixed within the vial and then aspirated into the syringe (e.g. by retraction of the plunger).
- the syringe In the case of a powder stored in the syringe (or if no pharmaceutical component is stored in the syringe) and a fluid component stored in the vial, the syringe would contain an air or gas volume sufficient to displace the liquid contents of the vial 2 so as to facilitate transfer of the fluid contents of the vial to the syringe for mixing. Note that mixing contemplates multiple injection and/or aspiration of the contents between the syringe and the vial, as well as swilling of the contents of the vial and/or the syringe.
- FIG. 28 a illustrates an embodiment of a pharmaceutical transfer assembly in a retracted or “unactivated” position wherein the same reference numerals are used to describe similar parts and only the differences are described.
- vial coupler 22 further includes an elongated rib segment 22 b adapted for accommodating cap portion 36 of syringe 66 within the vial coupler. Rib segment 22 b is adapted to enable receipt of syringe portion 36 to provide increased stability and structural integrity upon coupling with the vial.
- FIG. 28 a further shows upper portion 42 a of hub shoulder 42 is partially retained within the horizontal extensions 56 b of pawls 56 in the retracted position (rather than disposed beneath extensions 56 b as shown in FIG. 28), thereby providing further stabilization of the hub and needle assembly within the vial coupler 22 .
- FIG. 29 a illustrates the assembly of FIG. 28 a wherein syringe 66 is coupled to receiving end 404 of adapter 400 and the syringe advanced within rib segment 22 b to abut shoulder 22 b 1 , whereby the entire hub shoulder 42 moves past the resilient pawls 56 during advancement and the tip 40 a of cannula 40 penetrates the penetrable closure on vial 2 to create fluid communication between the vial and the syringe.
- FIG. 30 a illustrates the assembly of FIG. 28 a after detachment of the syringe from the adapter 400 whereby the bottom portion of hub shoulder 42 rests on and is retained by the top of horizontal extensions 56 b of pawls 56 .
- FIG. 30 b shows a plan view along lines A-A of FIG. 30 a which best illustrates the meshing of longitudinal ribs 22 c extending down the inner wall of vial coupler 22 with ribs 401 a formed about the circumference of retaining member 401 to slidably interlock to prevent rotation of retaining member 401 .
- Ribs 42 b formed on hub shoulder 42 are adapted to mesh with corresponding slots S in pawls 56 to prevent rotation of the hub shoulder and the needle and hub assembly.
- Syringe 66 may be pre-attached to the vial coupler assembly during the manufacturing stage by coupling luer 38 to receiving end 404 of adapter 400 .
- FIG. 28 b shows syringe cap portion 36 disposed within rib segment 22 b in the retracted position (i.e. not advanced within rib segment 22 b so as to abut shoulder 22 b 1 as shown in FIG. 29 a ).
- the syringe and vial coupler assembly may be pre-attached with the vial 2 separately packaged for subsequent attachment to the assembly by the user.
- FIGS. 31 - 33 illustrate an exemplary embodiment wherein vial coupler 312 includes retaining member or stopper 412 having a first portion in frictional engagement with the interior surface of pawls 56 and a second portion in frictional engagement with cannula 40 for maintaining the needle and hub assembly in a predetermined retracted (i.e. “unactivated”) position. Stopper 412 has at least a portion of its outer surface in contact engagement with the interior surface of resilient pawls 56 . Stopper 412 is disposed adjacent to the penetrable closure of vial 2 .
- An outer diameter of stopper 412 is sufficiently larger than the inner diameter of pawls 56 such that the stopper frictionally engages the pawls for maintaining the stopper in a predetermined position absent applying a longitudinal force to the stopper (i.e. when the assembly is in the retracted or “unactivated” position).
- Bore 413 is formed within a central interior portion of stopper 412 and is adapted for receiving the tip end of cannula 40 .
- the inner diameter of the bore is sufficiently smaller than the diameter of the cannula to permit insertion of a portion of the cannula into the bore such that the bore frictionally engages the cannula, thereby maintaining the cannula and hub assembly in a predetermined position within the vial coupler as shown in FIG. 31.
- Bore 413 may be a blind bore, extending only partially along the longitudinal axis of the stopper, or may be originally absent from the stopper, which is penetrable by the cannula upon advancement of the hub and needle assembly in response to application of sufficient longitudinal force in the direction toward vial 2 .
- stopper 412 may be formed of an elastomeric material such as rubber or other pliable material sufficient to frictionally engage both the interior surface of pawls 56 and the exterior surface of cannula 40 . Stopper 412 is sized such that both the stopper and the hub shoulder 412 can be accommodated within pawls 56 when the device is in the advanced position.
- stopper 412 serves to limit the degree of advancement of the hub shoulder within vial coupler 12 and accordingly limits the advancement of the needle 40 into the vial. As shown in FIGS. 31 - 32 , stopper 412 has lower portion 414 whose outer diameter is sized to frictionally engage a first interior portion 561 of pawls 56 . Upper portion 416 has an outer diameter sized to frictionally engage a second interior portion 563 . Stopper 412 further includes a body portion 418 of uniform diameter less than the interior diameter of pawls 56 . A conical head end portion 419 extending from upper portion 416 terminates in contact engagement with the outer surface of the penetrable closure of vial 2 .
- Cannula 40 is retained within hub shoulder 42 coupled to socket connector 41 .
- the cannula may either be staked within the hub assembly.
- socket connector 41 is a press or friction fit onto luer 38 of syringe 66 .
- Other connection means are contemplated, including, for example, threadingly mating socket connector 41 and luer 38 .
- FIG. 32 illustrates the syringe coupled to the hub and needle assembly before activation.
- the method for deploying the pharmaceutical delivery system comprises coupling luer 38 of syringe 66 to socket connector 41 ; advancing the syringe 66 and the hub and needle assembly longitudinally within the vial coupler 312 such that the cannula moves through the bore formed in stopper 412 and penetrates the penetrable closure on vial 2 to create fluid communication between the vial and the syringe.
- the shoulder 42 attached to the cannula, also moves through the vial coupler and is captured by the pawls 56 .
- a plunger rod inserted into flange end 68 projects the contents of the material in socket 24 into pharmaceutical vial 2 , as previously described.
- the assembly is then swilled to dissolve, mix or suspend the contents of vial 2 with that of the pharmaceutical component from the syringe.
- Withdrawing the plunger aspirates the contents of the vial 2 into the syringe 66 , and the syringe is decoupled from the connector 41 by detaching luer 38 to provide a syringe without needle but otherwise ready for use.
- the bottom portion of hub shoulder 42 rests on and is retained by the top of horizontal extensions 56 b of pawls 56 .
- the stopper and shoulder hub and needle are retained within the vial coupler 312 by pawls 56 , as shown in FIG. 33.
- FIGS. 31 a , 32 a and 33 a illustrate an exemplary pharmaceutical delivery system and successive stages of deployment of the system corresponding to that illustrated in FIGS. 31 - 33 and described above, but with the additional features as identified in FIGS. 28 a , 29 a and 30 a .
- vial coupler 312 further includes elongated rib segment 22 b adapted for accommodating cap portion 36 of syringe 66 within the vial coupler to provide increased stability and structural integrity upon coupling with the vial.
- FIG. 31 a further shows that upper portion 42 a of hub shoulder 42 is partially retained within the horizontal extensions 56 b of pawls 56 in the retracted position rather than disposed beneath extensions 56 b as shown in FIG. 31), thereby providing further stabilization of the hub and needle assembly within the vial coupler 312 .
- the syringe and vial coupler assembly may be pre-attached, with the vial 2 separately packaged for subsequent attachment to the assembly by the user.
- FIG. 31 b is a variation of the embodiment of FIG. 31 a showing a fully assembled device in the retracted position. Note that the syringe and vial coupler assembly may be pre-attached, with the vial 2 separately packaged for subsequent attachment to the assembly by the user.
- vial coupler 512 includes retaining member or stopper 612 mounted onto a portion of cannula 40 .
- the cannula extends longitudinally through the central interior portion of stopper 612 .
- Retaining member 612 may be frictionally fitted onto the cannula, or alternatively, molded as a top portion of hub shoulder 42 .
- retaining member 612 may be fixedly secured or staked onto the cannula by any well known means, such as adhesive bonding, welding, and the like. As shown in FIG.
- Extended rib segment 22 b is adapted for accommodating cap portion 36 of syringe 66 within the vial coupler to provide increased stability and structural integrity upon coupling with the vial. Shoulder 22 b 1 operates to prevent further insertion or advancement of the syringe within the vial coupler 512 beyond annular sleeve top surface 36 a .
- Retaining member 612 may be formed of a plastic or plastic-like material.
- the maximum diameter D of the retaining member is slightly less than the internal diameter of pawls 56 such that a clearance C exists between the retaining member and pawls for facilitating longitudinal sliding movement and guidance of the cannula as it is protracted forward (i.e. advanced) towards the vial in response to application of a longitudinal force.
- Retaining member 612 may also be formed of a rubber or elastomeric material, and having at least a portion of its outer surface frictionally engaged with the interior surface of pawls 56 for assisting in maintaining the cannula in a predetermined position absent applying a longitudinal force.
- the stopper 612 moves with the cannula and hub assembly to the advanced position wherein the cannula tip penetrates the penetrable closure.
- the stopper 612 is disposed in the upper portion 519 of pawls 56 , as shown in FIG. 35, with the bottom portion of hub shoulder 42 resting on and retained by the top of horizontal extensions 56 b of pawls 56 in lower portion 519 .
- Stopper 612 is sized such that both the stopper and the hub shoulder 42 can be accommodated within pawls 56 when the device is in the advanced position as shown in FIGS. 35 - 36 .
- FIG. 34 a is a variation of the embodiment of FIG. 34 showing a fully assembled device. Note that the syringe and vial coupler assembly may be pre-attached, with the vial 2 separately packaged for subsequent attachment to the assembly by the user.
- FIG. 37 shows yet another embodiment of a transfer device for transferring pharmaceutical components between a vial and a syringe according to an aspect of the invention.
- Vial coupler 222 comprises opposing first and second open axial ends 224 , 226 .
- First open end 224 includes a flanged portion 225 adapted for engaging an end of a medicine vial 2 having a penetrable closure 4 .
- Second open end 226 is adapted for receiving syringe 660 .
- Retaining member 228 extending inwardly from the interior surface of vial coupler 222 operates to engage and retain protractible luer 720 within the vial coupler.
- Protractible luer 720 comprises a luer body having internally threaded opening 722 for threadingly mating with an enlarged blunt mounting end 734 of syringe needle 40 . As shown in FIG. 37, hub portion 730 is fixedly secured to needle 40 at end 732 , opposite enlarged blunt mounting end 734 . Protractible luer 720 further comprises at an end opposite end 722 a female luer lock 724 having a threaded opening for releasably engaging a male luer lock (not shown) disposed beneath protective cap 380 on syringe 660 .
- Protractible luer body 720 includes on its annular outer surface 723 a set of detents 725 , 727 spaced apart from one another for enabling retaining member 228 to retain the protractible luer within the vial coupler 222 in either the retracted or advanced position.
- FIG. 37 illustrates the protractible luer body 720 in the retracted position.
- Longitudinal arm portion 229 of retaining member 228 is sized to fit between protrusions 725 , 727 (for example, snap fit) with protrusion 727 having edge 727 a serving to abut end 229 a to retain the luer in the retracted position.
- the method for deploying the pharmaceutical delivery system comprises coupling the male luer lock (not shown) of syringe 660 to female luer lock 724 of the protractible luer and advancing the syringe 660 longitudinally within the vial coupler 222 , causing a corresponding longitudinal movement of luer 720 .
- Tapered portion 725 b of protrusion 725 slides over arm portion 229 during advancement such that, upon completion, the arm is retained between detent edge 725 a and annular flange 723 .
- the arm 229 serves to abut the inner annular flange shoulder 723 a to limit the degree of insertion of the syringe and accordingly the advancement of the needle 40 into the vial.
- Ribs 726 formed about the circumference of luer body 720 cooperate in interlocking fashion with corresponding ribs (not shown) formed on the interior of arm 229 to prevent rotation of the protractible luer assembly, as shown in FIG. 37 a .
- the protractible luer remains fixed within the vial coupler with arm 229 confined by flange edge 723 a and protrusion edge 725 a .
- syringe 660 may be removed from luer 720 (by unthreading the male luer lock from end 724 ) and the rest of the pharmaceutical delivery system, including vial 2 , and the transfer assembly including the protractible luer can be safely discarded.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
A transfer device and method for deploying one or more pharmaceutical components between a medicine vial and a syringe.
Description
- This application is a continuation-in-part of co-pending patent application Ser. No. 09/668,159 filed on Sep. 25, 2000, which is a continuation-in-part of application Ser. No. 09/114,063, filed on Jul. 13, 1998, which is a continuation-in-part of International Patent Application PCT/CA97/00017, filed on Jan. 10, 1997, which is a continuation-in-part of application Ser. No. 08/584,041, filed Jan. 11, 1996 and now abandoned.
- The present invention is directed to a syringe adapter, and more particularly to a device that allows a user to reconstitute medicine in sealed vials.
- Many pharmaceutical preparations must be distributed as two or more separate components which can only be combined shortly before administration of the preparation, usually because the combined preparation is subject to rapid deterioration or otherwise unstable, and the components are only stable when stored separately. Typically at least one component of such a preparation is a liquid which acts as a solvent, diluent or carrier for the other component.
- Traditionally such preparations have been prepared shortly before administration by taking one component packaged in a conventional pharmaceutical vial having a neck closed by a penetrable elastomeric stopper secured to a neck of the vial by a cap, taking a second liquid component in a hypodermic syringe, injecting the second component into the vial through the stopper, swilling the vial impaled on the syringe to dissolve, dilute or suspend the first component in the second component, and aspirating the combined components back into the syringe by withdrawing its plunger. This procedure requires a degree of dexterity, is subject to the errors commonly associated with manual onsite preparation of pharmaceuticals, and may compromise sterility. If a third component is used, the procedure must be repeated.
- In endeavours to overcome these problems, many proposals have been made for systems to provide prepackaged two component pharmaceuticals, but these tend to suffer from one or more problems of their own such as complex and expensive structure requirements for specialized filling equipment, complex manipulation at the time of use, and often most serious of all, a heavy burden in time and expense in obtaining regulatory approval for a new product.
- U.S. Pat. No. 3,872,867 (Killinger) utilizes a tubular assembly incorporating a double ended cannula, into which two pharmaceutical vials are pressed in order to combine components in the two vials. The system requires that one of the vials is under vacuum at pressure, and merely results in a vial containing the combined product, which must still be transferred to a syringe for administration.
- U.S. Pat. No. 3,563,373 (Paulson) discloses an arrangement utilizing two cartridges in tandem for packaging a two component pharmaceutical, utilizing an intermediate assembly incorporating a double ended needle, which penetrates the piston of one cartridge and neck stopper of the other. The arrangement cannot utilize a standard pharmaceutical vial.
- U.S. Pat. No. 4,060,082 (Lindberg) also requires two syringes in tandem for combining a two component pharmaceutical, as well as specialized auxiliary pistons in the syringes.
- U.S. Pat. No. 4,583,971 (Bocquet et al) discloses apparatus for transferring liquid through a cannula from a flexible container to dissolve a pharmaceutical, and returning the solution to the flexible container. The system is dependent upon manipulation of a tangible closure through the flexible container and could not be used to transfer liquid from a syringe to a pharmaceutical vial and back again.
- U.S. Pat. No. 5,171,214 (Kolber et al) discloses a combination of a vial assembly, a syringe assembly, and an adapter for attaching the vial assembly to the syringe assembly so that a liquid constituent may be transferred from the syringe to the vial and the admixed compounds returned to the syringe. A special vial and special syringe are required, and indeed the system is predicated upon the use of a proprietary vial assembly.
- An object of the present invention is to provide a delivery system for two component pharmaceuticals which is economical to manufacture, easy to manipulate, and can minimize regulatory burdens.
- According to the invention, there is provided an activation assembly for preparing a prefilled syringe from separately prepackaged components of a multicomponent pharmaceutical preparation, the assembly comprising a two part tubular body; the body defining in a first part a first cylindrical recess at one end of a diameter to receive, as a sliding fit, a discharge end of cylindrical body of a protosyringe at which end is located a closure, broachable on activation of the protosyringe, the recess also receiving a substantial portion of the cylindrical body of the protosyringe, which contains a first, liquid component of the pharmaceutical preparation and which is provided at its opposite end with a piston displaceable longitudinally of the cylindrical body and forming a hermetic seal therewith; a second cylindrical recess defined in the other end of the tubular body by a second detachable part to receive a cap securing a penetrable closure at the neck of the pharmaceutical vial containing a second component of the pharmaceutical preparation; the tubular body defining in said first part a passage connecting the cylindrical recesses; a hub movable longitudinally of the tubular body within the passage; a cannula extending longitudinally of the tubular body from said hub to a distal end directed towards the second recess; a penetrable shield member covering the distal end of the cannula and located to contact a penetrable closure of a pharmaceutical vial inserted in the cylindrical recess, and a hollow cylindrical overcap concentric with the hub assembly and located within the tubular body in the first cylindrical recess, the overcap being connected to the hub to limit movement of the latter into the passage; the depth of the cylindrical recesses, the length of the passage connecting the recesses, the extent of the cannula from the hub, and the location of the overcap i the first cylindrical recess being such that upon a protosyringe received in the first cylindrical recess and a vial received in the second recess being displaced towards each other, the overcap is displaced onto the discharge end of the protosyringe and the hub moves longitudinally so that the cannula penetrates the penetrable shield member and the penetrable closure of the vial to place the cap of the protosyringe and the vial in fluid communication through the cannula; wherein the protosyringe and the vial can be driven directly towards each other to effect penetration of the shield member and the penetrable closure of the vial, wherein a portion of the hub supporting the cannula is separately formed and detachable from the hub assembly, the hub assembly having a luer on which said separately formed portion is releasably lodged, and wherein means is provided within the detachable part of the tubular assembly to detain, within the tubular assembly, said one end of the cannula when the cannula is driven into a position into a position penetrating the cap of the pharmaceutical vial.
- Two terms used in the preceding paragraph and elsewhere in this specification and the appended claims require mention. A ‘protosyringe’ is an assembly intended to form the basis of a prefilled syringe but requiring the addition of components to form a complete syringe. At minimum, it includes a cylindrical body containing at least a component of a pharmaceutical product, the body being closed at one end by a broachable closure and being at an opposite end with a piston connected to or provided with means for connection to an activating plunger so that the latter may be used to displace the contents of the body. Protosyringes include bottomless vials as described in my U.S. Pat. No. 5,364,369; cartridges; and prefilled syringes requiring at least addition of an overcap as defined below and introduction of a further component of the pharmaceutical product to provide a ready to use syringe. An ‘overcap’ is a cap adapted to be lodged on the cap of a protosyringe and providing means for supporting a needle or other instrumentality through which contents of a syringe formed from the protosyringe may be discharged. In some instances, a complete prefilled syringe itself may be used as a protosyringe if it has a luer connection closed by a cap of penetrable material over which an overcap may be received.
- The invention also extends to the combination of such an assembly with a protosyringe and/or pharmaceutical vials already engaged in their associated cylindrical recesses. If the protosyringe is already engaged in the first cylindrical recess, its free end may be covered by a removable cap to prevent accidental projection into the cylindrical bottom resulting in premature actuation of the assembly. When a protosyringe or vial is preengaged in its cylindrical recess, the associated sealing member in the assembly is in resilient contact with the penetrable closure of the vial in areas concentric with the cannula so as to help maintain sterility of areas of the sealing members and closures intended to be penetrated by the cannula.
- The hub assembly and a modified overcap may also be utilized in conjunction with a protosyringe or pharmaceutical vial to provide alternative delivery systems for pharmaceuticals contained in the protosyringe or vial.
- Further features of the invention will be apparent from the following description of embodiments of the invention.
- FIG. 1 is an exploded view of the components of an assembly according to the invention, including both a protosyringe, in this case a bottomless vial, and a pharmaceutical vial;
- FIG. 2 illustrates an assembly according to the invention, including a bottomless vial, as it might be shipped;
- FIG. 3 illustrates a similar assembly, but further including a pharmaceutical vial, ready for activation;
- FIG. 4 illustrates in part sectional view components of an assembly according to FIG. 3, but with upper components removed for clarity;
- FIG. 5 is a similar view to FIG. 4, but showing the illustrated components in the relationship which they assume after activation of the assembly in order to prepare a completed prefilled syringe;
- FIG. 6 is a view of the assembly corresponding to FIG. 3, after activation;
- FIG. 7 is a view of the assembly after the plunger has been pressed upwardly to transfer liquid from the bottomless vial to the pharmaceutical vial;
- FIG. 8 is a view showing a mixing step;
- FIG. 9 shows upper portions of the assembly being removed, leaving a syringe ready for application of a needle or other discharge means;
- FIG. 10 shows a partially exploded view of a modified embodiment of delivery system utilizing a different form of protosyringe;
- FIGS. 11 and 12 are fragmentary sectional views of an alternative form of syringe socket and associated parts which permit elements of the delivery system to be used in further embodiments of delivery system in conjunction with prefilled protosyringes or pharmaceutical vials;
- FIG. 13 shows in section a cap which may be applied to a luer on a hub portion of the embodiment of FIGS. 11 and 12 to enable the hub to be driven from the position to FIG. 11 to that of FIG. 12 to activate a prefilled protosyringe;
- FIG. 14 shows in an exploded view parts of an alternative activation system for use with the embodiment of FIGS. 11 and 12 so as to activate a syringe or vial for use in conjunction with a standard flexible mini-bag;
- FIG. 15 shows an assembled syringe ready for activation;
- FIG. 16 shows an activated syringe applied to a mini-bag;
- FIG. 17 is an exploded view illustrating components of a presently preferred modification of the embodiment of FIGS.1-9;
- FIG. 18 shows the parts shown in FIG. 17 assembled ready for use, less the plunger;
- FIGS. 19 and 20 illustrate a presently preferred modification of the embodiment of FIGS. 11 and 12;
- FIG. 21 illustrates the assembled components of a further embodiment of assembly according to the invention;
- FIG. 22 is an exploded view of components of a hub assembly used in the embodiment of FIG. 21;
- FIG. 23 illustrates a modification of the embodiment of FIG. 18, showing how the assembly of the invention may be used to activate pharmaceuticals having more than two components;
- FIG. 24 illustrates an assembly in accordance with a further embodiment of the invention;
- FIG. 25 is a flow diagram illustrating the preparation of assemblies in accordance with the embodiment of FIGS. 17 and 18; and
- FIGS. 26 and 27 are exploded and assembled views of a further embodiment of the invention.
- FIG. 28 is an exemplary illustration of a pharmaceutical delivery system including a pharmaceutical transfer assembly in a retracted or “unactivated” postion according to an embodiment of the invention.
- FIG. 28a is a variation of the embodiment of FIG. 28.
- FIG. 28b is a variation of the embodiment of FIG. 28a showing a fully assembled device.
- FIGS. 29 and 30 illustrate successive stages in deployment of the pharmaceutical delivery system of FIG. 28 for transfer of a pharmaceutical component between a vial and a syringe.
- FIGS. 29a and 30 a illustrate successive stages in deployment of the pharmaceutical delivery system of FIG. 28a for transfer of a pharmaceutical component between a vial and a syringe.
- FIG. 30b is a plan view taken along line A-A of the transfer device of FIG. 30A.
- FIG. 31 is an exemplary illustration of a pharmaceutical delivery system including a pharmaceutical transfer assembly in a retracted or “unactivated” postion according to another embodiment of the invention.
- FIG. 31a is a variation of the embodiment of FIG. 31.
- FIG. 31b is a variation of the embodiment of FIG. 31 a showing a fully assembled device.
- FIGS. 32 and 33 illustrate successive stages in deployment of the pharmaceutical delivery system of FIG. 31 for transfer of a pharmaceutical component between a vial and a syringe.
- FIGS. 32a and 33 a illustrate successive stages in deployment of the pharmaceutical delivery system of FIG. 31 a for transfer of a pharmaceutical component from a vial to a syringe.
- FIG. 34 is an exemplary illustration of a pharmaceutical delivery system including a pharmaceutical transfer assembly in a retracted or “unactivated” postion according to yet another embodiment of the invention.
- FIG. 34a is a variation of the embodiment of FIG. 34 showing a fully assembled device.
- FIGS. 35 and 36 illustrate successive stages in deployment of the pharmaceutical delivery system of FIG. 34 for transfer of a pharmaceutical component between a vial and a syringe.
- FIG. 37 is an exemplary illustration of a pharmaceutical delivery system including a pharmaceutical transfer assembly in a retracted or “unactivated” postion according to yet another embodiment of the invention.
- FIG. 37A is a perspective view of a portion of the transfer assembly shown in FIG. 37.
- Referring first to FIGS.1 to 3, the parts are shown of an assembly for preparing a syringe containing a pharmaceutical preparation, components A and B of which are contained respectively in a
pharmaceutical vial 2 and a protosyringe in the form of abottomless vial 4 consisting of acylindrical body 6, open at one end and provided with aneck 8 at its other end, the neck being closed by anelastomeric closure 10 secured in place by ametal cap 12 crimped over the neck. Apiston 14 is lodged in the open end of the body, the piston being provided withmeans 16 by which adetachable plunger 18 may be secured to the piston. The plunger will normally be shipped detached from the piston, both to reduce the overall length of the assembly, and to permit aremovable cap 20 to be applied over a projecting end of thebottomless vial 4 as shown in FIG. 2 so as to prevent inadvertent premature activation of the assembly. - At least one of the components A and B is liquid; usually it will be convenient to locate a liquid component in the bottomless vial but it would be possible to locate a solid component in the bottomless vial provided that the latter also contains an air or gas volume sufficient to displace liquid contents of the
vial 2. - Since a typical two component pharmaceutical for administration via a syringe comprises an active ingredient and a liquid solvent, diluent or carrier (hereinafter collectively referred to as diluent for convenience) which in the majority of cases will be one of only a few different types (most usually distilled water), it will usually be advantageous to place the active component in the
vial 2; this is because in many, if not most cases, a suitable vial package of the active ingredient will already be certified by regulatorycylindrical recess 31 into which may be slid thebody 6 of thebottomless vial 4, although not initially to the full extent permitted by the depth of the recess. - The
end portion 26 of the syringe socket includes aguide 52 with detents 53 for controlling longitudinal movement of ahub 34 having gappedlongitudinal ribs 33. The hub is formed at a front end with a liquid delivery conduit through a standard luer as utilized in the industry for coupling needles, or other delivery instrumentalities forming liquid delivery conduit extensions, to syringes and other sources of liquid pharmaceuticals. Such a luer comprises an internally threadedsocket 36 for locking a needle in place, and a taperedcentral spigot 38 for establishing a seal with a complementary socket on the needle. In the present instance, ahollow transfer needle 40 has asocket 41 lodged on the central spigot, but is not provided with threads to engage those of thesocket 36, so theneedle 40 may be pulled from thespigot 38. A taperedshoulder 42 is formed on thetransfer needle 40. Thehub 34 has a hollow needle orcannula 44 projecting from its end opposite thespigot 38 and in communication with a central passage in the spigot. A flexible needle sheath or shield 46 of thin rubber covers theneedle 44, having a portion 48 engaging a socket in the end of thehub 34, and a flattenedend 50 over the free end of the needle. Internally of theguide 52, theend portion 26 of the syringe socket also contains an extension of thecylindrical recess 31 dimensioned to provide an overcap which is a press fit over thecap 12 of thebottomless vial 4. - The
vial coupling 22 has a passage extending fromrecess 30 which receivesvial 2 to its internally threaded end, the passage being closed by a rubber stopper orshield 54. Between the rubber stopper and the internally threaded end ofcoupling 22, passage is formed internally withresilient pawls 56 which will detain theshoulder 42 of theneedle 40 when the latter is pressed past the pawls. - The assembly just described may be shipped on its own with neither vial installed, in which case a removable cover (not shown) will be required to cover the cylindrical recess in the
coupling 22 to maintain sterility, or with one or both vials installed (see FIGS. 2 and 3). When avial 2 is installed, any removable central portion of a cap 60 covering apenetrable closure 58 of the vial is flipped off, so that the penetrable closure may contact arib 64 on thestopper 54 to enclose an axial sterile zone of the tworubber parts closure 10, similarly exposed, contacts theend 50 of theneedle sheath 46 to provide protected zones on the contacting rubber parts. - In order to activate the assembly, after installation of the vials to provide the arrangement shown in FIG. 3, the bottomless vial is pressed into the
syringe socket 24, and theplunger 18 is attached to reach the condition shown in FIG. 6. - Thereafter, the assembly is inverted and
plunger 18 is activated to project the liquid content B from the bottomless vial into the pharmaceutical vial, (see FIG. 7), the assembly then being swilled as shown in FIG. 8 to dissolve, mix or suspend the contents of thevial 2 in the liquid, which is then aspirated back into the bottomless vial by withdrawing the plunger to reach a condition similar to that of FIG. 6, except that component A is now incorporated into component B to leave a product C in the bottomless vial. Thevial 22 is now unscrewed from thesyringe socket 24 and withdrawn, taking with it thetransfer needle 40 which is pulled off thespigot 38 by thepawls 56, thus leaving the luer ofhub 34 ready to receive a needle or other fluid connection instrumentality, and providing a completed ready to use syringe, filled with the two component pharmaceutical (see FIG. 9). Thehub 34 is retained on thecap 12 of the bottomless vial by thesyringe socket 24, with the needle providing a passage between thebody 6 and theluer - If the initial position of liquid and solid components is reversed, the step of FIG. 7 may be performed without inversion, with reciprocation of the syringe plunger being used to force air or gas from the
vial 4 to thevial 2, and liquid from thevial 2 to thevial 4. - A presently preferred modification of the assembly described above is shown in FIGS. 17 and 18, in which the same reference numerals are used to designate similar parts, and only the differences are described. In this modification, the
flange 35 of thehub 34 is extended to form the overcap, and theportion 26 of thesyringe socket 24 acts to receive the forward portion of this overcap when thesyringe body 6 is forced forward against and into the overcap during activation of the syringe. As best understood from FIG. 25, this rearrangement facilitates assembly. Thecap 20 is replaced by a driver in the form of a tubularcylindrical element 21, which snaps into the opening of thesyringe socket 24 as shown in FIG. 18 in a position in which it covers the rear of the protosyringe, and from which position it can be driven forward to activate the assembly. Theelement 21 has a bottom aperture to accommodate theplunger 18. Thestopper 54 is replaced by aflexible sheath 54 similar to theshield 46, since this is found to simplify assembly and provides complete coverage of theneedle 40. - It will be noted that the
plunger 18 in the embodiment of FIGS. 17 and 18 is provided withribs 18 at its distal end. This facilitates an alternative mode of activation of the assembly in which theplunger 18 is assembled to thepiston 14 prior to activation, and activation is achieved by pressure on the plunger. This initially drives the hub forward so that thecannula 40 penetrates the closure of hevial 2, then drives thecap 12 into theovercap 35 to penetrate the closure of the protosyringe so that the contents of the latter may be delivered into the vial. Theribs 18 a abut the periphery of the opening in the bottom of thedriver 21 as the plunger nears the end of its stroke, and presses forward the driver so that it snaps into thesleeve 24, thus signalling the completion of activation. - Various modifications are possible within the scope of the invention, the above description being of a presently preferred example. For instance, the
needle 40 could be permanently secured to thehub 34, and the pawls in the vial omitted. Such an arrangement does not provide the user with any choice as to the needle to be used on the finished syringe, and needle length may be severely limited by the need to avoid excess needle extent to thevial 2, which would make it difficult to aspirate its contents. - Likewise, the
bottomless vial 4 may be replaced by other forms of protosyringe such as cartridges, or by a prefilled syringe provided with an elastomeric closure covering a luer connection, the front end of the syringe accepting an overcap providing such a needle connection and acting to retain the hub. Such an arrangement is exemplified in FIG. 10, which shows the bottomless vial replaced by a protosyringe which is a conventional prefilled syringe having a conventional luer nozzle 101 protected by a protectiverubber sealing cap 100 over a front end of the syringe body, and thesyringe socket 24 is modified in shape to receive thebody 6 of the syringe, with longitudinalinternal ribs 102 to grip the syringe body. As before, acap 20 prevents the syringe body from being driven fully into thesyringe socket 24 until activation is required, and theend 50 of theshield 46 rests against thecap 100 to help maintain sterility of the zones to be penetrated by theneedle 44. - Yet further forms of protosyringe may be employed. For example, a known form of diluent vial comprises a
body 6 in the form of a glass tube with a piston at both ends. The piston at one end is similar to thepiston 14 with an extension similar to theextension 16. The piston at the other end fulfils the function of theneck 8,stopper 10 andcap 12 of the bottomless vial shown in FIG. 1. In conventional use, this other end of the vial is inserted into an open end of a sleeve which at its other end supports a luer or needle externally and an axial hollow pin projecting internally. The piston at the other end of the vial has an axial passage, through the piston and an outward extension of the piston, closed at its outer end by a bung which is displaced by the hollow pin on insertion of the vial into the sleeve, thus establishing communication between the needle or luer and the interior of the vial. Protosyringe from a vial into a syringe is completed by applying a plunger to the piston at the first end. This type of protosyringe can be substituted in the present invention for that shown in FIG. 1 or FIG. 17. During activation, theovercap needle 44 penetrates thesheath 46 and displaces the bung. The bung may be replaced by an integral septum in the passage of the piston which is penetrated by theneedle 44. - The syringe socket itself may be made detachable from the completed syringe except for the overcap, or may be truncated in length as shown in FIGS. 11 and 12. It will be seen that the
syringe socket 24 is shortened and reduced in diameter to receive thecap 12 of a bottomless vial, the syringe socket being pushed down over thecap 12 to engage the shoulder of thesyringe body 6. - On activation of the syringe the
hub 34 is driven downwardly relative to theend portion 26 of thesocket 24 from the position shown in FIG. 11 to the position shown in FIG. 12. In the position shown in FIG. 11, theend 50 of therubber shield 46 rests against theclosure 10 so as to provide a protected contact zone, which is penetrated by theneedle 44 on thehub 34 as the hub is driven downwardly through theguide 52 until aflange 35 on the bottom of thehub 34 contacts theclosure 10. At this point theneedle 44 establishes communication with the interior of thebody 6 of the protosyringe. - FIG. 21 shows how the arrangement of FIGS. 11 and 12 (or FIGS. 19 and 20 considered below) may be used in an arrangement in which the assembly is activated by insertion of the
vial 2. As best seen in FIG. 22, thecomponent 42 is lengthened and modified so that it, thepenetrable shield 54 on thecannula 40, and thecannula 40 itself, project into thevial socket 32. On insertion of thevial 2, theshield 54 is pressed into a recess in thearrangement 42 so that it is penetrated by the cannula, which also penetrates the closure of thevial 2, and the vial closure presses on thecomponent 42 so as to drive thecannula 44 through its sheath or shield and the penetrable closure of the protosyringe. If the modification of FIGS. 19 and 20 is used, with ahub 34 modified as shown in FIG. 22 so that theflange 35 provides the overcap, this driving action also drives theovercap 35 onto the cap of the protosyringe. If the arrangement of FIGS. 11 and 12 is used, the cap of the protosyringe is already lodged in the overcap. - FIG. 13 illustrates an alternative means of driving the
hub 34. Theluer spigot 38 of thehub 34 is covered by a conventionalmoulded cover 104, shown in section in FIG. 13, screwed into thesocket 36 and providing a convenient driver for the hub which can be unscrewed and discarded preparatory to fitting a needle to the luer of the hub. - FIGS. 14 and 15 illustrate an alternative driver arrangement, making use of a known type of adapter used to couple syringes to flexible mini-bags so that the contents of the syringe may be discharged into the bag and mixed with the contents of the latter. The adapter106 consists of a
tube 108 which has an internally threadedsocket 118 at one end for screwing in the present case on to complementary external threads on theportion 26 of asyringe socket 24, andslots 110 at the other end to engage lugs on a nipple of the bag so that the nipple is guided into the adapter concentrically aligned with aneedle 112 fitted to thespigot 38 of thehub 34. Acap 114 covers the slotted end of thetube 108, and has a concentric internaltubular extension 116 that sheathes theneedle 112, and extends thesocket 36 of thehub 34 when the latter is in the position shown in FIG. 11, with thetube 108 extending only part way into thecap 114. Pushing further on the cap will force thehub 34 from the position shown in FIG. 11 to the position shown in FIG. 12, thus activating the syringe. Thecap 114 may then be removed, and the syringe applied to a mini-bag as shown in FIG. 16. Alternatively thetube 10 may also be removed providing a ready to use syringe. - Instead of a protosyringe in the form of a bottomless vial, the arrangement of FIGS. 11, 12,14 and 15 may also be used to activate a regular pharmaceutical vial so that its contents may be mixed with those of a mini-bag or other flexible bag. Liquid from the flexible bag may be caused to enter the activated vial through the needle, and the admixed contents of the vial then allowed to run back into the bag through the needle by suitable manipulation of the bag and the attached activated vial.
- The arrangement shown in FIGS. 11 and 12 may also be modified as shown in FIGS. 19 and 20 by extending the
flange 35 of thehub 34 to form the overcap (see also FIG. 22). In order to accommodate downward movement of the overcap while preventing inward movement of the protosyringe, the reduced diameter portion of the syringe socket is extended downward as at 27 to form a shoulder limiting insertion of the protosyringe. - FIG. 23 shows a modification of the embodiment of FIGS. 17 and 18 to allow preparation of a three component pharmaceutical. The
vial socket 22 is bifurcated, as is thecomponent 42, so as to provide twovial sockets 30, and two needles which are not seen since they are covered bysheaths 54. On activation of the assembly by driving thedriver 21 into thesyringe socket 24, the closures of the vials will be penetrated simultaneously, enabling liquid from theprotosyringe body 6 to enter bothvials 2 and dissolve or suspend their contents. On activation,latch members 56 engage thecomponent 42 to retain it, as in previous embodiments. - A
further vial socket 30 and a further branch of thecomponent 42 may be provided for each additional component to be handled. - Referring now to FIG. 24, the principles of the invention may also be utilized with protosyringes in the form of a shell vial (or as shown, the functional equivalent of a shell vial produced by reversing a
bottomless vial 206 as described in U.S. Pat. No. 5,364,369A and applying adriver cap 220 to its cap end). Such shell vials are normally formed into a completed syringe by screwing a threadedextension 216 of apiston 214 into a free end of a plunger stem within a concentric syringe shell connected to the other end of the plunger. A double ended needle extends axially of the plunger stem and out of its other end. Screwing theextension 216 fully onto the plunger stem causes the needle to penetrate the piston so that the contents of the shell vial may be expelled through the needle by driving the vial onto the plunger stem. Such an arrangement is described in U.S. Pat. No. 5,171,214A already referenced above. In the present instance, asyringe socket 224 provides the shell, and the hub assembly utilized in the embodiment of FIGS. 1 -10, modified as shown in FIGS. 17 and 18, is further modified by providing anelongated cannula 244 surrounded by aconcentric plunger stem 218 positioned on the cannula by passing through aflange 245 and entering theovercap 35. The length of thecannula 244 is such that it ends short of a penetrable septum (not shown) within thepiston 21 with the components in the unactivated state shown in FIG. 24, with thepiston extension 216 screwed into a threaded socket at the bottom ofstem 218. - The assembly is activated by driving the shell vial upwardly so that a reduced
diameter portion 219 of thestem 228 enters theovercap 35, permitting thecannula 244 to perforate the septum in the piston. Further upward movement causes the cannula supported at the upper end of the hub to penetrate thesheath 64 and the penetrable closure of thevial 2, whereafter activation can proceed as previously described save that theshell vial 206 is manipulated in place of a conventional plunger. - Referring now to FIG. 25, there is shown a flow diagram of the preparation of an assembly in accordance with the invention, specifically the embodiment of FIGS. 17 and 18.
- Starting at the top left, the
parts hub assembly 300, which is then sterilized by gamma radiation (step 320). Within a clean room 314 (top right) theparts protosyringe 304 to the cap of which theovercap 35 is applied, but not far enough for the cannula within theovercap 35 to penetrate the shield orsheath 46, to providesubassembly 306, which then passes through aninspection station 316. - In the
meanwhile parts subassembly 302 and, together with theplunger 18, sterilized by gamma radiation at 322. Theassembly 306 of protosyringe and hub assembly is inserted into theassembly 302 under a laminar flow hood to provide theassembly 308, whereafter, in the same environment, avial 2, from which any protective metal disc on the cap has been flipped off, is inserted into the vial socket of theassembly 308, which corresponds exactly to that of FIG. 18. The contacting surface of the penetrable closure 58 (see FIG. 1) of thevial 2 and thesurface 50 of theshield 64 are sterilized by a high intensity ultraviolet flash or anantiseptic spray 318 during this step, whereafter the resultingassembly 310 together with theplunger 18 is sealed into aplastic tray 312. The tray is vacuum formed with a recess shaped to correspond to the profile of theassembly 310. In particular, it is advantageous that this recess snugly embraces the narrower portion of theactuator 21 to avoid any possibility of inadvertent activation prior to use occasioned by shock or rough handling. - Variations are of course possible in this procedure. For example, the
protosyringe 304 like the vial might be preproduced and terminally sterilized, and assembled to the hub assembly to produce theassembly 306 in a similar manner to combination ofassemblies - In the embodiments described above, activation of the protosyringe involves penetration of the closure of the protosyringe by a second cannula on the hub, but the invention is also applicable to protosyringes activated by other means. In U.S. Pat. No. 3,967,759 (Baldwin), there is disclosed a protosyringe in which the closure at the capped end of the body of the protosyringe is a plug lodged in an end of a tubular body, which closure is breached by ejection of the plug into a hollow interior of the cap such that the contents of the syringe may bypass the plug within the cap.
- Such a protosryinge is activated by application of fluid pressure to the plug by the application in turn of longitudinal pressure to the piston of the protosyringe by a plunger, and thus the second cannula and its associated sheath is not required.
- This arrangement is exemplified in FIGS. 26 and 27, in which the same reference numerals are used to identify the same parts as in FIGS.1-8 or 17, and only the points of difference will be discussed in detail. The components shown in the left hand portions of FIG. 26, with the exception of a
filter 400, are essentially identical to the corresponding components of the embodiment of FIGS. 17 and 18, but the protosyringe shown in the right hand of FIG. 26 is essentially similar to that described with reference to FIGS. 1-4 of U.S. Pat. No. 3,967,759 (Baldwin), the text and drawings of which are incorporated herein by reference, except that thepiston retainer 402 pressed into the rear of thebody 6 is formed without the external flange 25 shown in the Baldwin patent, and the connector 37 of the Baldwin patent is replaced by a moreconventional luer connector cap 12, which otherwise corresponds to thecap 31 of the Baldwin patent, and is secured to thebody 6 by means of aflange 404 pressed onto the body. Theplug 10 corresponds to the plug 51 of the Baldwin patent, and may be formed with ribs similar to the ribs 53 of Baldwin or other means to ensure that, once the plug moves forward from thebody 6 into thecap 12, the seal formed by the plug remains broached, and liquid can bypass the plug. There are other systems known using displaceable plugs generally similar to that disclosed in the Baldwin patent but differing in detail in the means used to ensure that the plug remains bypassed once broached, and these could also be utilized. - An
adaptor 400 containing a filter may be provided secured to theconnector 41 on thecannula 40, the adaptor being a press fit on theluer 38, such that when thecannula 40 is captured by thedetents 56 and theportion 22 is removed, theadaptor 400 discarded with thecannula 40 and theportion 22. This enables a filter, incorporated in theadaptor 400, to be utilized during transfer of liquid between thevial 2 and the protosyringe during an activation process, so that any particulate may be removed from the reconstituted pharmaceutical as it is drawn back into the protosyringe. - The activation process is generally quite similar to that previously described. Referring to FIG. 27, pressing down on the
activation cap 21 causes the latter to move into the open end of thesocket 24 and press thepiston retainer 402 at the rear end of thebody 6 so as to move thecap 12 into theovercap 26. This moves the hub assembly formed by theluer 34,adaptor 400 andcannula 40 upwardly within thesleeve 22 until thecannula 40 pierces the closure of thevial 2. Theplunger 18 can then be attached to thepiston 14, and on applying pressure to the plunger, theplug 10 is moved forward to broach the closure of the protosyringe at its capped end, allowing the contents of the syringe to be discharged through thecannula 40 into thevial 2. After admixture (See FIGS. 4-9), the dissolved pharmaceutical is withdrawn back into the protosyringe through thecannula 40 and the filter inadaptor 400, and the filled syringe is removed as shown in FIG. 9, leaving behind thecannula 40 and theadaptor 400 containing the filter, and presenting theluer 34 for attachment of a hypodermic needle or other injection instrumentality. - In another possible variation, the portion of
cap 12 beyond thebody 6 has a smaller rather than larger internal diameter than thebody 6, and theplug 10 is initially lodged in that portion of thecap 12. The 44 of the FIG. I or 17 embodiment is replaced by an activator rod, and the hub is made axially movable relative to the protosyringe as in the previous embodiments, so that on actuation of the syringe, the rod is projected against theplug 10 in thecap 12 and dislodges it into thebody 6 to broach the seal of the protosyringe. - FIGS.28-30 illustrate an embodiment of a syringe device similar to that of FIGS. 26 and 27, with like reference numerals used to indicate like parts, wherein
vial coupler 22 includes a first open end having avial socket 32 for receiving the cap end ofvial 2 having apenetrable closure 4, and a second open end for receiving a mounting end ofsyringe 66.Vial coupler 22 further includes a series ofribs 22 c formed oninner wall 22 a and extending longitudinally down the length of the vial coupler.Adaptor 400 comprises annular retainingmember 401 appropriately sized for retention within aportion 23 viadetents ribs 22 c. The detents operate to impede longitudinal movement of the adapter so as to confine the adapter toportion 23 when the device is in the retracted position or “unactivated” state, as shown in FIG. 28. This in turn maintains the position of the hub and needle assembly comprisinghub shoulder 42 andsocket connector 41, with hollow needle orcannula 40 retained within the shoulder portion. As shown in FIG. 28, the cannula is staked within the hub shoulder providing an enlarged blunt mounting end received byadapter 400. In an exemplary embodiment, retainingmember 401 also operates as a filter for trapping particulate matter traversing the passageway betweensyringe 66 andvial 2 when the device is in the advanced position or “activated” state (i.e. when the vial is penetrated by needle or cannula 40) resulting from a longitudinal force applied toadapter 400 of magnitude sufficient to move retainingmember 401 from beyond the region confined by the detents toward vial 2 (see FIG. 29). A series ofribs 401 a formed about the circumference of retainingmember 401 are adapted to slidably interlock with correspondinglongitudinal ribs 22 c (best seen in the embodiment shown in FIG. 30b) extending downvial coupler 22 to prevent rotation of retainingmember 401 and the needle and hub assembly.Luer 38 is formed onsyringe 66 forcoupling adapter 400 at externally threaded open receivingend 404 via cooperating internal threads formed on the syringe luer portion. Other well known means forreleasably coupling syringe 66 toadapter 400 may be employed (e.g. press fit or snap fit).Adapter 400 further includes open receivingend 406 which is secured tosocket connector 41 for establishing the passageway through the hub and needle arrangement. Other well known means for securingadapter 400 toconnector 41 of the hub and needle arrangement may be employed, including for example, press fit or snap fit, adhesive coupling and the like. -
Syringe 66 further includessocket 24 capable of carrying a transferable material such as a fluid for transfer between the syringe and thevial 2 throughvial coupler 22. Still referring to FIGS. 28-30, the method for deploying the pharmaceutical delivery system comprisescoupling luer 38 ofsyringe 66 toadapter 400; advancing thesyringe 66 and thus the adapter 400 (and hub and needle assembly) longitudinally within thevial coupler 22 from the retracted position to the advanced position whereby the hub shoulder portion moves past theresilient pawls 56 during advancement and thetip 40 a ofcannula 40 penetrates the penetrable closure onvial 2 to create fluid communication between the vial and the syringe. A plunger rod (not shown) is inserted intoflange end 68 in the direction illustrated by arrow A (FIG. 29) to project the contents of the material insocket 24 intopharmaceutical vial 2. The assembly is then swilled to dissolve, mix or suspend the contents ofvial 2 with that of the pharmaceutical component from the syringe. Withdrawing the plunger aspirates the contents of thevial 2 into thesyringe 66, and the syringe is detached from the adapter 400 (and hub and needle assembly) by unscrewingluer 38 fromadapter end 404 to provide a syringe without needle but otherwise ready for use (see FIG. 30). The bottom portion ofhub shoulder 42 rests on and is retained by the top ofhorizontal extensions 56 b ofpawls 56.Pawls 56 thus prevent retraction of thehub shoulder 42 from the advanced position, thus retaining the hub and needle assembly including the adapter withinvial coupler 22. - Note that the method for deploying the pharmaceutical delivery system using a
pre-filled syringe 66 described herein is applicable for both single and multi-component pharmaceutical transfer between a vial and syringe. That is,vial 2 may contain a pharmaceutical component (e.g. a fluid or powder) and the prefilled syringe may contain another pharmaceutical component (e.g. a fluid or powder). In the case of a fluid component stored in the syringe, the fluid contents of the syringe are injected into the vial (e.g. by depression of a plunger); the components are then mixed within the vial and then aspirated into the syringe (e.g. by retraction of the plunger). In the case of a powder stored in the syringe (or if no pharmaceutical component is stored in the syringe) and a fluid component stored in the vial, the syringe would contain an air or gas volume sufficient to displace the liquid contents of thevial 2 so as to facilitate transfer of the fluid contents of the vial to the syringe for mixing. Note that mixing contemplates multiple injection and/or aspiration of the contents between the syringe and the vial, as well as swilling of the contents of the vial and/or the syringe. - In a modification to the embodiment depicted in FIGS.28-30 and described above, FIG. 28a illustrates an embodiment of a pharmaceutical transfer assembly in a retracted or “unactivated” position wherein the same reference numerals are used to describe similar parts and only the differences are described. As shown in FIG. 28a,
vial coupler 22 further includes anelongated rib segment 22 b adapted for accommodatingcap portion 36 ofsyringe 66 within the vial coupler.Rib segment 22 b is adapted to enable receipt ofsyringe portion 36 to provide increased stability and structural integrity upon coupling with the vial.Shoulder 22 b 1 operates to prevent further insertion or advancement of the syringe within thevial coupler 22 beyond annular sleevetop surface 36 a. FIG. 28a further showsupper portion 42 a ofhub shoulder 42 is partially retained within thehorizontal extensions 56 b ofpawls 56 in the retracted position (rather than disposed beneathextensions 56 b as shown in FIG. 28), thereby providing further stabilization of the hub and needle assembly within thevial coupler 22. - FIG. 29a illustrates the assembly of FIG. 28a wherein
syringe 66 is coupled to receivingend 404 ofadapter 400 and the syringe advanced withinrib segment 22 b toabut shoulder 22 b 1, whereby theentire hub shoulder 42 moves past theresilient pawls 56 during advancement and thetip 40 a ofcannula 40 penetrates the penetrable closure onvial 2 to create fluid communication between the vial and the syringe. FIG. 30a illustrates the assembly of FIG. 28a after detachment of the syringe from theadapter 400 whereby the bottom portion ofhub shoulder 42 rests on and is retained by the top ofhorizontal extensions 56 b ofpawls 56. FIG. 30b shows a plan view along lines A-A of FIG. 30a which best illustrates the meshing oflongitudinal ribs 22 c extending down the inner wall ofvial coupler 22 withribs 401 a formed about the circumference of retainingmember 401 to slidably interlock to prevent rotation of retainingmember 401.Ribs 42 b formed onhub shoulder 42 are adapted to mesh with corresponding slots S inpawls 56 to prevent rotation of the hub shoulder and the needle and hub assembly. -
Syringe 66 may be pre-attached to the vial coupler assembly during the manufacturing stage by couplingluer 38 to receivingend 404 ofadapter 400. FIG. 28b showssyringe cap portion 36 disposed withinrib segment 22 b in the retracted position (i.e. not advanced withinrib segment 22 b so as toabut shoulder 22 b 1 as shown in FIG. 29a). In a preferred embodiment, the syringe and vial coupler assembly may be pre-attached with thevial 2 separately packaged for subsequent attachment to the assembly by the user. - FIGS.31-33 illustrate an exemplary embodiment wherein
vial coupler 312 includes retaining member orstopper 412 having a first portion in frictional engagement with the interior surface ofpawls 56 and a second portion in frictional engagement withcannula 40 for maintaining the needle and hub assembly in a predetermined retracted (i.e. “unactivated”) position.Stopper 412 has at least a portion of its outer surface in contact engagement with the interior surface ofresilient pawls 56.Stopper 412 is disposed adjacent to the penetrable closure ofvial 2. An outer diameter ofstopper 412 is sufficiently larger than the inner diameter ofpawls 56 such that the stopper frictionally engages the pawls for maintaining the stopper in a predetermined position absent applying a longitudinal force to the stopper (i.e. when the assembly is in the retracted or “unactivated” position).Bore 413 is formed within a central interior portion ofstopper 412 and is adapted for receiving the tip end ofcannula 40. The inner diameter of the bore is sufficiently smaller than the diameter of the cannula to permit insertion of a portion of the cannula into the bore such that the bore frictionally engages the cannula, thereby maintaining the cannula and hub assembly in a predetermined position within the vial coupler as shown in FIG. 31.Bore 413 may be a blind bore, extending only partially along the longitudinal axis of the stopper, or may be originally absent from the stopper, which is penetrable by the cannula upon advancement of the hub and needle assembly in response to application of sufficient longitudinal force in the direction towardvial 2. In an exemplary embodiment,stopper 412 may be formed of an elastomeric material such as rubber or other pliable material sufficient to frictionally engage both the interior surface ofpawls 56 and the exterior surface ofcannula 40.Stopper 412 is sized such that both the stopper and thehub shoulder 412 can be accommodated withinpawls 56 when the device is in the advanced position. Also,stopper 412 serves to limit the degree of advancement of the hub shoulder withinvial coupler 12 and accordingly limits the advancement of theneedle 40 into the vial. As shown in FIGS. 31-32,stopper 412 haslower portion 414 whose outer diameter is sized to frictionally engage a firstinterior portion 561 ofpawls 56.Upper portion 416 has an outer diameter sized to frictionally engage a secondinterior portion 563.Stopper 412 further includes abody portion 418 of uniform diameter less than the interior diameter ofpawls 56. A conicalhead end portion 419 extending fromupper portion 416 terminates in contact engagement with the outer surface of the penetrable closure ofvial 2. -
Cannula 40 is retained withinhub shoulder 42 coupled tosocket connector 41. The cannula may either be staked within the hub assembly. In the embodiment of FIGS. 31-32,socket connector 41 is a press or friction fit ontoluer 38 ofsyringe 66. Other connection means are contemplated, including, for example, threadinglymating socket connector 41 andluer 38. FIG. 32 illustrates the syringe coupled to the hub and needle assembly before activation. The method for deploying the pharmaceutical delivery system comprisescoupling luer 38 ofsyringe 66 tosocket connector 41; advancing thesyringe 66 and the hub and needle assembly longitudinally within thevial coupler 312 such that the cannula moves through the bore formed instopper 412 and penetrates the penetrable closure onvial 2 to create fluid communication between the vial and the syringe. Theshoulder 42, attached to the cannula, also moves through the vial coupler and is captured by thepawls 56. A plunger rod inserted into flange end 68 projects the contents of the material insocket 24 intopharmaceutical vial 2, as previously described. The assembly is then swilled to dissolve, mix or suspend the contents ofvial 2 with that of the pharmaceutical component from the syringe. Withdrawing the plunger aspirates the contents of thevial 2 into thesyringe 66, and the syringe is decoupled from theconnector 41 by detachingluer 38 to provide a syringe without needle but otherwise ready for use. The bottom portion ofhub shoulder 42 rests on and is retained by the top ofhorizontal extensions 56 b ofpawls 56. The stopper and shoulder hub and needle are retained within thevial coupler 312 bypawls 56, as shown in FIG. 33. - FIGS. 31a, 32 a and 33 a illustrate an exemplary pharmaceutical delivery system and successive stages of deployment of the system corresponding to that illustrated in FIGS. 31-33 and described above, but with the additional features as identified in FIGS. 28a, 29 a and 30 a. In particular, as shown in FIGS. 31a, 32 a, and 33 a,
vial coupler 312 further includeselongated rib segment 22 b adapted for accommodatingcap portion 36 ofsyringe 66 within the vial coupler to provide increased stability and structural integrity upon coupling with the vial.Shoulder 22 b 1 operates to prevent further insertion or advancement of the syringe within thevial coupler 312 beyond annular sleevetop surface 36 a. FIG. 31a further shows thatupper portion 42 a ofhub shoulder 42 is partially retained within thehorizontal extensions 56 b ofpawls 56 in the retracted position rather than disposed beneathextensions 56 b as shown in FIG. 31), thereby providing further stabilization of the hub and needle assembly within thevial coupler 312. It is understood that the syringe and vial coupler assembly may be pre-attached, with thevial 2 separately packaged for subsequent attachment to the assembly by the user. - FIG. 31b is a variation of the embodiment of FIG. 31a showing a fully assembled device in the retracted position. Note that the syringe and vial coupler assembly may be pre-attached, with the
vial 2 separately packaged for subsequent attachment to the assembly by the user. - A modification of the assembly described above is shown in FIGS.34-36, in which the same reference numerals are used to describe similar parts and only the differences are described. In the exemplary embodiment illustrated in FIGS. 34-36,
vial coupler 512 includes retaining member orstopper 612 mounted onto a portion ofcannula 40. The cannula extends longitudinally through the central interior portion ofstopper 612. Retainingmember 612 may be frictionally fitted onto the cannula, or alternatively, molded as a top portion ofhub shoulder 42. Still further, retainingmember 612 may be fixedly secured or staked onto the cannula by any well known means, such as adhesive bonding, welding, and the like. As shown in FIG. 34, the bottom surface 612 b of retainingmember 612 rests on top ofhorizontal extensions 56 b in lower portion 518 ofpawls 56 when in the retracted or “inactivated” position and is disposed adjacent to the hub shoulder and socket arrangement shown in FIG. 34. In this manner the cannula, which is coupled to themember 612, is maintained in a predetermined position prior to fluid coupling.Extended rib segment 22 b is adapted for accommodatingcap portion 36 ofsyringe 66 within the vial coupler to provide increased stability and structural integrity upon coupling with the vial.Shoulder 22 b 1 operates to prevent further insertion or advancement of the syringe within thevial coupler 512 beyond annular sleevetop surface 36 a. FIG. 34 further shows thatupper portion 42 a ofhub shoulder 42 is partially retained within thehorizontal extensions 56 b ofpawls 56 in the retracted position, thereby providing further stabilization of the hub and needle assembly within thevial coupler 512. Retainingmember 612 may be formed of a plastic or plastic-like material. The maximum diameter D of the retaining member is slightly less than the internal diameter ofpawls 56 such that a clearance C exists between the retaining member and pawls for facilitating longitudinal sliding movement and guidance of the cannula as it is protracted forward (i.e. advanced) towards the vial in response to application of a longitudinal force. Retainingmember 612 may also be formed of a rubber or elastomeric material, and having at least a portion of its outer surface frictionally engaged with the interior surface ofpawls 56 for assisting in maintaining the cannula in a predetermined position absent applying a longitudinal force. - Upon application of a longitudinal force to
socket 41 in the direction ofvial 2 sufficient to overcome the resistive force of the pawls againsthub shoulder 42, thestopper 612 moves with the cannula and hub assembly to the advanced position wherein the cannula tip penetrates the penetrable closure. Upon advancement, thestopper 612 is disposed in the upper portion 519 ofpawls 56, as shown in FIG. 35, with the bottom portion ofhub shoulder 42 resting on and retained by the top ofhorizontal extensions 56 b ofpawls 56 in lower portion 519.Shoulder 22 b 1 abuts annular sleevetop surface 36 a to prevent further insertion or advancement of the syringe within thevial coupler 22 and accordingly limits the advancement of theneedle 40 into the vial.Stopper 612 is sized such that both the stopper and thehub shoulder 42 can be accommodated withinpawls 56 when the device is in the advanced position as shown in FIGS. 35-36. Upon advancement of the stopper, needle and hub assembly to the activated position and reconstitution of the pharmaceutical components in thevial 2 andsyringe socket 24, the syringe is unscrewed from the connector socket and the stopper, shoulder hub and needle are retained within thevial coupler 512 bypawls 56, as shown in FIG. 36. - FIG. 34a is a variation of the embodiment of FIG. 34 showing a fully assembled device. Note that the syringe and vial coupler assembly may be pre-attached, with the
vial 2 separately packaged for subsequent attachment to the assembly by the user. - FIG. 37 shows yet another embodiment of a transfer device for transferring pharmaceutical components between a vial and a syringe according to an aspect of the invention. Vial coupler222 comprises opposing first and second open axial ends 224, 226. First
open end 224 includes aflanged portion 225 adapted for engaging an end of amedicine vial 2 having apenetrable closure 4. Secondopen end 226 is adapted for receivingsyringe 660. Retainingmember 228 extending inwardly from the interior surface of vial coupler 222 operates to engage and retainprotractible luer 720 within the vial coupler.Protractible luer 720 comprises a luer body having internally threadedopening 722 for threadingly mating with an enlarged bluntmounting end 734 ofsyringe needle 40. As shown in FIG. 37,hub portion 730 is fixedly secured toneedle 40 atend 732, opposite enlarged bluntmounting end 734.Protractible luer 720 further comprises at an end opposite end 722 afemale luer lock 724 having a threaded opening for releasably engaging a male luer lock (not shown) disposed beneathprotective cap 380 onsyringe 660.Protractible luer body 720 includes on its annular outer surface 723 a set ofdetents member 228 to retain the protractible luer within the vial coupler 222 in either the retracted or advanced position. - FIG. 37 illustrates the
protractible luer body 720 in the retracted position. Longitudinal arm portion 229 of retainingmember 228 is sized to fit betweenprotrusions 725, 727 (for example, snap fit) withprotrusion 727 having edge 727 a serving to abut end 229 a to retain the luer in the retracted position. The method for deploying the pharmaceutical delivery system comprises coupling the male luer lock (not shown) ofsyringe 660 tofemale luer lock 724 of the protractible luer and advancing thesyringe 660 longitudinally within the vial coupler 222, causing a corresponding longitudinal movement ofluer 720. Tapered portion 725 b ofprotrusion 725 slides over arm portion 229 during advancement such that, upon completion, the arm is retained between detent edge 725 a andannular flange 723. The arm 229 serves to abut the inner annular flange shoulder 723 a to limit the degree of insertion of the syringe and accordingly the advancement of theneedle 40 into the vial.Ribs 726 formed about the circumference ofluer body 720 cooperate in interlocking fashion with corresponding ribs (not shown) formed on the interior of arm 229 to prevent rotation of the protractible luer assembly, as shown in FIG. 37a. Once the transfer assembly has been deployed into the advanced position, the protractible luer remains fixed within the vial coupler with arm 229 confined by flange edge 723 a and protrusion edge 725 a. Upon reconstitution of the contents of the vial and syringe socket,syringe 660 may be removed from luer 720 (by unthreading the male luer lock from end 724) and the rest of the pharmaceutical delivery system, includingvial 2, and the transfer assembly including the protractible luer can be safely discarded. - Although illustrated and described herein with reference to certain specific embodiments, the present invention is nevertheless not intended to be limited to the details shown. Rather, various modifications may be made in the details within the scope and range of equivalents of the claims and without departing from the spirit of the invention.
Claims (27)
1. A syringe safety device configured to form a fluid coupling between a sealed vial and a syringe, the syringe safety device comprising: a tubular connector having opposing first and second axial open ends, the first open axial end being adapted to engage an end of a medicine vial with stopper; and a sliding joint received in the second open axial end of the tubular connector, the sliding joint having opposing first and second open axial ends and a passageway between the first and second axial open ends, the first axial open end being adapted to engage with a mounting end of a syringe needle, the second axial end of the sliding joint further being adapted to releasably engage at least a releasable needle receiver on a distal end of a barrel of a syringe without needle, the syringe being releasably removable from the sliding joint after fluid coupling with the vial through the passageway of the sliding joint without removal of the sliding joint from the tubular connector and without the needle.
2. The syringe safety device according to claim 1 further comprising a syringe needle with one pointed end and one enlarged blunt mounting end, the needle being non-releasably captured in the tubular connector with the sliding joint.
3. The syringe safety device according to claim 2 wherein the sliding joint is slidably mounted in the tubular connector and the first axial end of the sliding joint is engaged with the blunt mounting end of the enclosed needle to support and axially move the needle in the tubular connector and sufficiently to form a leak resistant fluid coupling between the blunt mounting end of the needle and the sliding joint.
4. The syringe safety device according to claim 2 wherein the first axial end of the sliding joint is configured to releasably mate with the blunt mounting end of the enclosed needle.
5. The syringe safety device according to claim 1 wherein the second axial end of the sliding joint is open and has an inner chamber exposed at the second end of the tubular connector, the inner chamber being configured to releasably receive at least a needle mount provided on the distal end of the syringe to removably mount a needle to the distal end of the syringe.
6. The syringe safety device according to claim 1 in combination with the sealed vial.
7. The combination of claim 6 wherein the syringe is prefilled with a fluid.
8. The syringe safety device according to claim 1 , wherein the tubular connector includes a set of detents formed on an inner surface thereof, and wherein the sliding joint includes a retaining member disposed between the detents prior to fluid coupling for retaining the needle in a predetermined position.
9. The syringe safety device according to claim 8 , wherein the retaining member comprises an in-line filter.
10. The syringe safety device according to claim 1 , further comprising a retaining member mounted on the needle and operable for retaining the needle in a predetermined position prior to fluid coupling.
11. The syringe safety device according to claim 10 , wherein the retaining member frictionally engages an inner surface of the tubular connector for retaining the needle in the predetermined position prior to fluid coupling.
12. The syringe safety device according to claim 10 , wherein the retaining member is made of a material penetrable by the needle in response to application of a force onto the sliding joint in a longitudinal direction toward the vial.
13. The syringe safety device according to claim 11 , wherein the retaining member is disposed adjacent to the vial.
14. The syringe safety device according to claim 10 , wherein the retaining member is disposed adjacent to the sliding joint prior to fluid coupling.
15. The syringe safety device according to claim 2 , wherein the syringe is a conventional syringe.
16. A transfer device for transferring a pharmaceutical component between a sealed vial and a syringe, comprising:
a tubular connector having opposing first and second axial open ends, the first open axial end being adapted to engage an end of a medicine vial having a penetrable closure;
a sliding joint received in the second open axial end of the tubular connector, the sliding joint having opposing first and second open axial ends and a passageway between the first and second axial open ends, the first axial open end being adapted to engage with an enlarged blunt mounting end of a syringe needle, the second axial end of the sliding joint further being adapted to releasably engage at least a releasable needle receiver on a distal end of a barrel of a conventional syringe without needle, the syringe being releasably removable from the sliding joint after coupling with the vial through the passageway of the sliding joint without removal of the sliding joint from the tubular connector and without the needle.
17. The device of claim 16 , wherein the pharmaceutical component transferred comprises a fluid.
18. The device of claim 16 , wherein the medicine vial contains a fluid, and wherein the sliding joint fluidly couples with the vial through the passageway of the sliding joint.
19. A transfer device for transferring fluid between a sealed vial and a syringe, comprising:
a tubular connector having opposing first and second axial open ends, the first open axial end being adapted to engage an end of a medicine vial having a penetrable closure;
a syringe needle; and
a movable adapter disposed in the tubular connector, the adapter having opposing first and second open axial ends and a passageway between the first and second axial open ends, the first axial open end being adapted to engage with a mounting end of the syringe needle, the second axial end of the adapter further being adapted to releasably engage at least a releasable needle receiver on a distal end of a barrel of a syringe without needle, the syringe being releasably removable from the adapter after coupling with the vial through the passageway of the adapter without removal of the adapter from the tubular connector and without the needle.
20. A transfer device for transferring a pharmaceutical component from a vial to a syringe, comprising:
a tubular connector having opposing first and second axial open ends, the first open axial end being adapted to engage an end of a medicine vial having a penetrable closure, the second open end being adapted to receive a portion of a syringe;
a syringe needle; and
a protractible luer assembly having a first portion coupled to the syringe needle and a second portion for releasably coupling to the syringe, the luer assembly having a passageway for pharmaceutical component transfer therebetween, the luer assembly longitudinally protractible from a first retracted position within the tubular connector to a second advanced position, wherein in the first retracted position a retaining assembly formed on the interior of the tubular connector engages a first portion of the luer assembly and the syringe needle is contained within the tubular connector apart from the penetrable closure, and wherein in the second advanced position, advancement of the first portion of the luer assembly from the retaining assembly advances the syringe needle to pierce the penetrable closure for establishing the pharmaceutical component transfer, wherein the syringe is releasably removable from the protractible luer assembly upon completion of the pharmaceutical component transfer and the syringe needle and protractible luer is retained in said tubular connector.
21. The device of claim 20 , wherein the interior of the tubular connector engages a second portion of the luer assembly when the device is in the advanced position.
22. The device of claim 20 , wherein the retaining assembly comprises an arm segment extending from the interior of the tubular connector and in contact engagement with protrusions formed on the luer assembly for retaining therein.
23. A method for deploying a pharmaceutical component between a vial and a syringe, comprising:
providing a tubular transfer device having a first end receiving a medicine vial having a penetrable closure containing a pharmaceutical component, and a protractible luer assembly disposed in the interior of the transfer device, the protractible luer assembly having a first end coupled to a syringe needle, the syringe needle extending towards the first end of the tubular transfer device receiving the vial, a second end opposite the first end, and a passageway therebetween, the luer assembly protractible from a first retracted position to a second advanced position within the tubular transfer device;
coupling a portion of a syringe without needle to the second end of the protractible luer assembly of the transfer device, the syringe having a socket for accommodating another pharmaceutical component;
applying a longitudinal force through the syringe to the protractible luer assembly to advance the assembly from the first retracted position wherein the syringe needle is apart from the vial, to the second advanced position wherein the syringe needle penetrates the penetrable closure of the vial to establish a passage between the vial and the syringe through the passageway of the luer assembly, the luer assembly being retained in the second advanced position within the tubular transfer device;
transferring at least one pharmaceutical component between the vial and the syringe socket through the passage; and
detaching the portion of the syringe from the second end of the protractible luer assembly, whereby the protractible luer assembly and syringe needle is retained within the tubular transfer device upon detachment, and whereby the syringe containing the transferred at least one pharmaceutical component is presented for attachment to another syringe needle.
24. The method of claim 23 , wherein the step of transferring comprises injecting a fluid from the syringe into the vial via the passage; and aspirating the contents of the vial into the syringe via the passage.
25. The method of claim 24 , further comprising the step of mixing the contents of the vial after the step of injecting and before the step of aspirating.
26. The method of claim 24 , further comprising mixing the contents of the syringe after the step of aspirating.
27. A transfer device for transferring a pharmaceutical component from a vial to a syringe, comprising:
a tubular connector having opposing first and second axial open ends, the first open axial end being adapted to engage an end of a medicine vial having a penetrable closure, the second open end being adapted to receive a portion of a syringe;
a syringe needle;
a protractible luer assembly having a first portion coupled to the syringe needle and a second portion for releasably coupling to the syringe, the luer assembly having a passageway for pharmaceutical component transfer therebetween, the luer assembly longitudinally protractible from a first retracted position within the tubular connector wherein the syringe needle is contained within the tubular connector apart from the penetrable closure, to a second advanced position toward the vial, wherein the syringe needle pierces the penetrable closure for establishing the pharmaceutical component transfer via the passageway; and
means disposed in the tubular connector for retaining the protractible luer assembly including the needle within the tubular connector upon advancement of the protractible luer assembly to the advanced position and release of the second portion of the luer assembly from the syringe.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/367,607 US20040024354A1 (en) | 1996-01-11 | 2003-02-14 | Transfer device and method for transferring a pharmaceutical component between a vial and a syringe |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58404996A | 1996-01-11 | 1996-01-11 | |
PCT/CA1997/000017 WO1997025015A1 (en) | 1996-01-11 | 1997-01-10 | Delivery system for pharmaceuticals packed in pharmaceutical vials |
US09/114,063 US6149623A (en) | 1996-01-11 | 1998-07-13 | Delivery system for pharmaceuticals packed in pharmaceutical vials |
US09/668,159 US6638244B1 (en) | 1996-01-11 | 2000-09-25 | Delivery system for multi-component pharmaceuticals |
US10/367,607 US20040024354A1 (en) | 1996-01-11 | 2003-02-14 | Transfer device and method for transferring a pharmaceutical component between a vial and a syringe |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/668,159 Continuation-In-Part US6638244B1 (en) | 1996-01-11 | 2000-09-25 | Delivery system for multi-component pharmaceuticals |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040024354A1 true US20040024354A1 (en) | 2004-02-05 |
Family
ID=24335709
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/114,063 Expired - Lifetime US6149623A (en) | 1996-01-11 | 1998-07-13 | Delivery system for pharmaceuticals packed in pharmaceutical vials |
US09/668,159 Expired - Lifetime US6638244B1 (en) | 1996-01-11 | 2000-09-25 | Delivery system for multi-component pharmaceuticals |
US10/367,607 Abandoned US20040024354A1 (en) | 1996-01-11 | 2003-02-14 | Transfer device and method for transferring a pharmaceutical component between a vial and a syringe |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/114,063 Expired - Lifetime US6149623A (en) | 1996-01-11 | 1998-07-13 | Delivery system for pharmaceuticals packed in pharmaceutical vials |
US09/668,159 Expired - Lifetime US6638244B1 (en) | 1996-01-11 | 2000-09-25 | Delivery system for multi-component pharmaceuticals |
Country Status (11)
Country | Link |
---|---|
US (3) | US6149623A (en) |
EP (1) | EP0928182B1 (en) |
JP (1) | JP4187790B2 (en) |
AT (1) | ATE217181T1 (en) |
AU (1) | AU726244B2 (en) |
CA (1) | CA2242915C (en) |
DE (1) | DE69712499T2 (en) |
DK (1) | DK0928182T3 (en) |
ES (1) | ES2176661T3 (en) |
PT (1) | PT928182E (en) |
WO (1) | WO1997025015A1 (en) |
Cited By (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060200095A1 (en) * | 2005-03-02 | 2006-09-07 | Steube Gregory A | Blunt tip vial access cannula |
US20080215030A1 (en) * | 2005-08-08 | 2008-09-04 | Eli Lilly And Company | Assembly for Filling a Container of a Delivery Device with a Pharmaceutical |
US20090247962A1 (en) * | 2008-03-31 | 2009-10-01 | Tyco Healthcare Group Lp | Vial Access Device |
US20090326485A1 (en) * | 2008-06-30 | 2009-12-31 | Carlyon James L | Blunt tip vial access cannula and method for manufacture |
US20100036319A1 (en) * | 2007-02-01 | 2010-02-11 | Pa Knowledge Limited | Auto injector |
US20110087164A1 (en) * | 2008-04-01 | 2011-04-14 | Yukon Medical, Llc | Dual container fluid transfer device |
US20110106045A1 (en) * | 2009-10-30 | 2011-05-05 | Reynolds David L | Inter vial transfer system |
US20110106021A1 (en) * | 2009-10-30 | 2011-05-05 | Revance Therapeutics, Inc. | Device and Method for Topical Application of Therapeutics or Cosmetic Compositions |
USD655017S1 (en) | 2010-06-17 | 2012-02-28 | Yukon Medical, Llc | Shroud |
WO2012063230A1 (en) * | 2010-11-14 | 2012-05-18 | Medimop Medical Projects Ltd | Inline liquid drug medical device having rotary flow control member |
USD669980S1 (en) | 2010-10-15 | 2012-10-30 | Medimop Medical Projects Ltd. | Vented vial adapter |
US8317743B2 (en) | 2007-09-18 | 2012-11-27 | Medimop Medical Projects Ltd. | Medicament mixing and injection apparatus |
USD674088S1 (en) | 2012-02-13 | 2013-01-08 | Medimop Medical Projects Ltd. | Vial adapter |
USD681230S1 (en) | 2011-09-08 | 2013-04-30 | Yukon Medical, Llc | Shroud |
US8435210B2 (en) | 2007-04-17 | 2013-05-07 | Medimop Medical Projects Ltd. | Fluid control device with manually depressed actuator |
US8608723B2 (en) | 2009-11-12 | 2013-12-17 | Medimop Medical Projects Ltd. | Fluid transfer devices with sealing arrangement |
US8684994B2 (en) | 2010-02-24 | 2014-04-01 | Medimop Medical Projects Ltd. | Fluid transfer assembly with venting arrangement |
US8753325B2 (en) | 2010-02-24 | 2014-06-17 | Medimop Medical Projects, Ltd. | Liquid drug transfer device with vented vial adapter |
US8752598B2 (en) | 2011-04-17 | 2014-06-17 | Medimop Medical Projects Ltd. | Liquid drug transfer assembly |
CN104159626A (en) * | 2012-03-08 | 2014-11-19 | 贝克顿·迪金森公司 | Drug reconstitution system |
US8905994B1 (en) | 2011-10-11 | 2014-12-09 | Medimop Medical Projects, Ltd. | Valve assembly for use with liquid container and drug vial |
USD720451S1 (en) | 2012-02-13 | 2014-12-30 | Medimop Medical Projects Ltd. | Liquid drug transfer assembly |
US8979792B2 (en) | 2009-11-12 | 2015-03-17 | Medimop Medical Projects Ltd. | Inline liquid drug medical devices with linear displaceable sliding flow control member |
US8998875B2 (en) | 2009-10-01 | 2015-04-07 | Medimop Medical Projects Ltd. | Vial assemblage with vial and pre-attached fluid transfer device |
USD734868S1 (en) | 2012-11-27 | 2015-07-21 | Medimop Medical Projects Ltd. | Drug vial adapter with downwardly depending stopper |
USD737436S1 (en) | 2012-02-13 | 2015-08-25 | Medimop Medical Projects Ltd. | Liquid drug reconstitution assembly |
US9125992B2 (en) | 2011-09-16 | 2015-09-08 | Melvin A. Finke | Fluid delivery device with filtration |
US9283324B2 (en) | 2012-04-05 | 2016-03-15 | Medimop Medical Projects, Ltd | Fluid transfer devices having cartridge port with cartridge ejection arrangement |
US9339438B2 (en) | 2012-09-13 | 2016-05-17 | Medimop Medical Projects Ltd. | Telescopic female drug vial adapter |
USD757933S1 (en) | 2014-09-11 | 2016-05-31 | Medimop Medical Projects Ltd. | Dual vial adapter assemblage |
USD765837S1 (en) | 2013-08-07 | 2016-09-06 | Medimop Medical Projects Ltd. | Liquid transfer device with integral vial adapter |
USD767124S1 (en) | 2013-08-07 | 2016-09-20 | Medimop Medical Projects Ltd. | Liquid transfer device with integral vial adapter |
USD769444S1 (en) | 2012-06-28 | 2016-10-18 | Yukon Medical, Llc | Adapter device |
WO2017125920A1 (en) * | 2016-01-21 | 2017-07-27 | Teva Medical Ltd. | Luer lock adaptor |
US9795536B2 (en) | 2012-08-26 | 2017-10-24 | Medimop Medical Projects, Ltd. | Liquid drug transfer devices employing manual rotation for dual flow communication step actuations |
US20170304525A1 (en) * | 2014-10-08 | 2017-10-26 | Vetter Pharma-Fertigung GmbH & Co. KG | System and method for providing an injection |
USD801522S1 (en) | 2015-11-09 | 2017-10-31 | Medimop Medical Projects Ltd. | Fluid transfer assembly |
US9801786B2 (en) | 2013-04-14 | 2017-10-31 | Medimop Medical Projects Ltd. | Drug container closure for mounting on open-topped drug container to form drug reconstitution assemblage for use with needleless syringe |
US9839580B2 (en) | 2012-08-26 | 2017-12-12 | Medimop Medical Projects, Ltd. | Liquid drug transfer devices |
US9943463B2 (en) | 2013-05-10 | 2018-04-17 | West Pharma. Services IL, Ltd. | Medical devices including vial adapter with inline dry drug module |
USD832430S1 (en) | 2016-11-15 | 2018-10-30 | West Pharma. Services IL, Ltd. | Dual vial adapter assemblage |
US10278897B2 (en) | 2015-11-25 | 2019-05-07 | West Pharma. Services IL, Ltd. | Dual vial adapter assemblage including drug vial adapter with self-sealing access valve |
US10285907B2 (en) | 2015-01-05 | 2019-05-14 | West Pharma. Services IL, Ltd. | Dual vial adapter assemblages with quick release drug vial adapter for ensuring correct usage |
US10357429B2 (en) | 2015-07-16 | 2019-07-23 | West Pharma. Services IL, Ltd. | Liquid drug transfer devices for secure telescopic snap fit on injection vials |
WO2019152589A1 (en) * | 2018-02-02 | 2019-08-08 | Becton, Dickinson And Company | Syringe assembly |
US10391233B2 (en) * | 2015-04-20 | 2019-08-27 | Tgel Bio Co., Ltd. | Drug delivery kit, and apparatus and method for preparing drug delivery system |
US10646404B2 (en) | 2016-05-24 | 2020-05-12 | West Pharma. Services IL, Ltd. | Dual vial adapter assemblages including identical twin vial adapters |
US10688295B2 (en) | 2013-08-07 | 2020-06-23 | West Pharma. Services IL, Ltd. | Liquid transfer devices for use with infusion liquid containers |
US10765604B2 (en) | 2016-05-24 | 2020-09-08 | West Pharma. Services IL, Ltd. | Drug vial adapter assemblages including vented drug vial adapter and vented liquid vial adapter |
US10772797B2 (en) | 2016-12-06 | 2020-09-15 | West Pharma. Services IL, Ltd. | Liquid drug transfer devices for use with intact discrete injection vial release tool |
US10806671B2 (en) | 2016-08-21 | 2020-10-20 | West Pharma. Services IL, Ltd. | Syringe assembly |
US10806667B2 (en) | 2016-06-06 | 2020-10-20 | West Pharma. Services IL, Ltd. | Fluid transfer devices for filling drug pump cartridges with liquid drug contents |
CN111867546A (en) * | 2018-03-20 | 2020-10-30 | 贝克顿迪金森有限公司 | Connection arrangement for closed system transfer of fluids |
USD903864S1 (en) | 2018-06-20 | 2020-12-01 | West Pharma. Services IL, Ltd. | Medication mixing apparatus |
US10945921B2 (en) | 2017-03-29 | 2021-03-16 | West Pharma. Services IL, Ltd. | User actuated liquid drug transfer devices for use in ready-to-use (RTU) liquid drug transfer assemblages |
US10953216B2 (en) | 2003-10-30 | 2021-03-23 | Simplivia Healtcare Ltd. | Safety drug handling device |
USD917693S1 (en) | 2018-07-06 | 2021-04-27 | West Pharma. Services IL, Ltd. | Medication mixing apparatus |
USD923812S1 (en) | 2019-01-16 | 2021-06-29 | West Pharma. Services IL, Ltd. | Medication mixing apparatus |
USD923782S1 (en) | 2019-01-17 | 2021-06-29 | West Pharma. Services IL, Ltd. | Medication mixing apparatus |
USD954253S1 (en) | 2019-04-30 | 2022-06-07 | West Pharma. Services IL, Ltd. | Liquid transfer device |
USD956958S1 (en) | 2020-07-13 | 2022-07-05 | West Pharma. Services IL, Ltd. | Liquid transfer device |
US11554215B2 (en) | 2017-06-08 | 2023-01-17 | Novartis Ag | Injection device and injection solution transferring system |
US11642285B2 (en) | 2017-09-29 | 2023-05-09 | West Pharma. Services IL, Ltd. | Dual vial adapter assemblages including twin vented female vial adapters |
WO2023081145A1 (en) * | 2021-11-03 | 2023-05-11 | Merck Sharp & Dohme Llc | Vial-to-syringe converter and methods of making and using same |
US11918542B2 (en) | 2019-01-31 | 2024-03-05 | West Pharma. Services IL, Ltd. | Liquid transfer device |
USD1043974S1 (en) | 2022-04-22 | 2024-09-24 | West Pharma. Services IL, Ltd. | Liquid transfer device |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6223786B1 (en) | 1998-11-14 | 2001-05-01 | Pen Jet Corporation | Apparatus and method for mixing medication and filling an ampule of a needle-less injector |
US6474369B2 (en) | 1995-05-26 | 2002-11-05 | Penjet Corporation | Apparatus and method for delivering a lyophilized active with a needle-less injector |
GB9611562D0 (en) * | 1996-06-03 | 1996-08-07 | Applied Research Systems | Device |
AU2002301323B2 (en) * | 1997-12-04 | 2005-06-16 | Baxter International Inc | Sliding reconstitution device with seal |
US6475183B1 (en) | 1998-06-03 | 2002-11-05 | Baxter International Inc. | Direct dual filling device for sealing agents |
GB9819962D0 (en) | 1998-09-15 | 1998-11-04 | Weston Medical Ltd | Needleless injection cartridge |
DE29818721U1 (en) * | 1998-10-21 | 2000-03-02 | Medico Development Investment Co., Ascona | Injection device |
AU1719800A (en) | 1998-11-13 | 2000-06-05 | Elan Pharma International Limited | Drug delivery systems and methods |
US6302160B2 (en) * | 1998-11-14 | 2001-10-16 | Pen Jet Corporation | Apparatus and method for filling an ampule of a needle-less injector |
CA2274290A1 (en) | 1999-06-09 | 2000-12-09 | Duoject Medical Systems Inc. | Delivery system for multi-component pharmaceuticals, and prefilled protosyringe for use therein |
AU2001232912A1 (en) * | 2000-01-21 | 2001-07-31 | Jet Medica, L.L.C. | Needleless syringe adaptor |
US7544189B2 (en) * | 2000-10-10 | 2009-06-09 | Meridian Medical Technologies, Inc. | Needle and hub assembly for automatic injector |
JP2002177392A (en) | 2000-11-08 | 2002-06-25 | West Pharmaceutical Services Inc | Safety device of syringe |
US6551298B1 (en) * | 2000-11-21 | 2003-04-22 | Jack Y. Zhang | Controlled medicament security enclosure system |
US20020087118A1 (en) | 2000-12-29 | 2002-07-04 | Duoject Medical Systems Inc. | Pharmaceutical delivery system |
JP4163961B2 (en) * | 2001-03-27 | 2008-10-08 | イーライ リリー アンド カンパニー | Kit including a side-spout syringe needle for preparing medication in an infusion pen cartridge |
US20030032935A1 (en) * | 2001-08-10 | 2003-02-13 | Scimed Life Systems, Inc. | Packages facilitating convenient mixing and delivery of liquids |
KR100431704B1 (en) * | 2001-08-13 | 2004-05-17 | 주식회사 대웅 | Container plus syringe system |
US6802828B2 (en) * | 2001-11-23 | 2004-10-12 | Duoject Medical Systems, Inc. | System for filling and assembling pharmaceutical delivery devices |
KR100511350B1 (en) * | 2002-02-09 | 2005-08-31 | 엘지.필립스 엘시디 주식회사 | A liquid crystal dispensing apparatus with a nozzle protecting device |
US7410109B2 (en) * | 2002-02-07 | 2008-08-12 | Lg Display Co., Ltd. | Liquid crystal dispensing apparatus with nozzle protecting device |
US7462366B2 (en) | 2002-03-29 | 2008-12-09 | Boston Scientific Scimed, Inc. | Drug delivery particle |
US6644365B1 (en) | 2002-04-19 | 2003-11-11 | Baxter International, Inc. | Tilting direct dual filling device |
AU2003240000A1 (en) | 2002-06-12 | 2003-12-31 | Boston Scientific Limited | Bulking agents |
US7842377B2 (en) * | 2003-08-08 | 2010-11-30 | Boston Scientific Scimed, Inc. | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient |
US8012454B2 (en) | 2002-08-30 | 2011-09-06 | Boston Scientific Scimed, Inc. | Embolization |
US7883490B2 (en) | 2002-10-23 | 2011-02-08 | Boston Scientific Scimed, Inc. | Mixing and delivery of therapeutic compositions |
US20060155257A1 (en) * | 2002-11-08 | 2006-07-13 | Reynolds David L | Pharmaceutical delivery systems and methods for using same |
US7678333B2 (en) * | 2003-01-22 | 2010-03-16 | Duoject Medical Systems Inc. | Fluid transfer assembly for pharmaceutical delivery system and method for using same |
ATE465709T1 (en) * | 2003-01-22 | 2010-05-15 | Duoject Inc | PHARMACEUTICAL DELIVERY SYSTEMS |
US7976823B2 (en) | 2003-08-29 | 2011-07-12 | Boston Scientific Scimed, Inc. | Ferromagnetic particles and methods |
JP2005113004A (en) * | 2003-10-08 | 2005-04-28 | Shin Etsu Chem Co Ltd | Semiconductor device |
US7736671B2 (en) | 2004-03-02 | 2010-06-15 | Boston Scientific Scimed, Inc. | Embolization |
US8173176B2 (en) | 2004-03-30 | 2012-05-08 | Boston Scientific Scimed, Inc. | Embolization |
US7311861B2 (en) | 2004-06-01 | 2007-12-25 | Boston Scientific Scimed, Inc. | Embolization |
US7294119B2 (en) * | 2004-06-10 | 2007-11-13 | Safety Syringes, Inc. | Passive delivery system diluents mixing and delivery |
KR20060011645A (en) * | 2004-07-30 | 2006-02-03 | 주식회사 엘지생명과학 | Drugs mixing assembly |
US7731678B2 (en) | 2004-10-13 | 2010-06-08 | Hyprotek, Inc. | Syringe devices and methods for mixing and administering medication |
US8425550B2 (en) | 2004-12-01 | 2013-04-23 | Boston Scientific Scimed, Inc. | Embolic coils |
CA2588888A1 (en) * | 2004-12-03 | 2006-06-08 | Duoject Medical Systems Inc. | Cartridge, device and method for pharmaceutical storage, mixing and delivery |
CN101146562B (en) | 2004-12-09 | 2011-11-30 | 韦斯特制药服务公司 | Coupling for an auto-injection device |
US20060184103A1 (en) * | 2005-02-17 | 2006-08-17 | West Pharmaceutical Services, Inc. | Syringe safety device |
US7766900B2 (en) | 2005-02-21 | 2010-08-03 | Biomet Manufacturing Corp. | Method and apparatus for application of a fluid |
US7727555B2 (en) | 2005-03-02 | 2010-06-01 | Boston Scientific Scimed, Inc. | Particles |
US7858183B2 (en) | 2005-03-02 | 2010-12-28 | Boston Scientific Scimed, Inc. | Particles |
US7963287B2 (en) | 2005-04-28 | 2011-06-21 | Boston Scientific Scimed, Inc. | Tissue-treatment methods |
JP2008540039A (en) * | 2005-05-16 | 2008-11-20 | マリンクロッド・インコーポレイテッド | Multi-stage syringe and method of using the same |
US9463426B2 (en) | 2005-06-24 | 2016-10-11 | Boston Scientific Scimed, Inc. | Methods and systems for coating particles |
JP5058998B2 (en) * | 2005-07-18 | 2012-10-24 | ウェスト ファーマシューティカル サービシズ インコーポレイテッド | Automatic injection syringe with venting means |
US8007509B2 (en) | 2005-10-12 | 2011-08-30 | Boston Scientific Scimed, Inc. | Coil assemblies, components and methods |
US8257338B2 (en) * | 2006-10-27 | 2012-09-04 | Artenga, Inc. | Medical microbubble generation |
CA2626864C (en) | 2005-11-09 | 2015-06-02 | Hyprotek, Inc. | Syringe devices, components of syringe devices, and methods of forming components and syringe devices |
US7988675B2 (en) * | 2005-12-08 | 2011-08-02 | West Pharmaceutical Services Of Delaware, Inc. | Automatic injection and retraction devices for use with pre-filled syringe cartridges |
US8152839B2 (en) | 2005-12-19 | 2012-04-10 | Boston Scientific Scimed, Inc. | Embolic coils |
US8101197B2 (en) | 2005-12-19 | 2012-01-24 | Stryker Corporation | Forming coils |
US7947368B2 (en) | 2005-12-21 | 2011-05-24 | Boston Scientific Scimed, Inc. | Block copolymer particles |
US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
US20090182300A1 (en) * | 2006-03-06 | 2009-07-16 | Novo Nodisk A/S | Drug Mixing Device |
US20090216184A1 (en) * | 2006-03-07 | 2009-08-27 | Novo Nordisk A/S | Drug storage and delivery device |
CA2834152C (en) | 2006-05-25 | 2016-07-05 | Bayer Healthcare Llc | Reconstitution device |
ATE471732T1 (en) * | 2006-05-30 | 2010-07-15 | Lilly Co Eli | MODULE FOR A DEVICE FOR INJECTING MEDICINAL PRODUCTS |
WO2007147741A1 (en) * | 2006-06-21 | 2007-12-27 | Novo Nordisk A/S | A one-hand operated drug mixing and expelling device |
ATE525102T1 (en) * | 2006-07-19 | 2011-10-15 | Mallinckrodt Llc | SYRINGE ARRANGEMENT WITH RADIATION SHIELDING |
US7981090B2 (en) | 2006-10-18 | 2011-07-19 | Baxter International Inc. | Luer activated device |
US8221363B2 (en) | 2006-10-18 | 2012-07-17 | Baxter Healthcare S.A. | Luer activated device with valve element under tension |
US7753338B2 (en) | 2006-10-23 | 2010-07-13 | Baxter International Inc. | Luer activated device with minimal fluid displacement |
US8414927B2 (en) | 2006-11-03 | 2013-04-09 | Boston Scientific Scimed, Inc. | Cross-linked polymer particles |
US9044378B2 (en) | 2007-05-31 | 2015-06-02 | Safety Syringes, Inc. | Anti-needle stick safety device or system for use with drugs requiring reconstitution |
US8475404B2 (en) | 2007-08-21 | 2013-07-02 | Yukon Medical, Llc | Vial access and injection system |
US9522097B2 (en) | 2007-10-04 | 2016-12-20 | Hyprotek, Inc. | Mixing/administration syringe devices, protective packaging and methods of protecting syringe handlers |
US8002737B2 (en) | 2007-10-04 | 2011-08-23 | Hyprotek, Inc. | Mixing/administration syringe devices, protective packaging and methods of protecting syringe handlers |
EP2214757A1 (en) * | 2007-11-22 | 2010-08-11 | Novo Nordisk Health Care AG | Medical mixing device |
WO2009102720A1 (en) | 2008-02-11 | 2009-08-20 | Safety Syringes, Inc. | Reconstitution means for safety device |
US8518272B2 (en) | 2008-04-04 | 2013-08-27 | Biomet Biologics, Llc | Sterile blood separating system |
US8998880B2 (en) * | 2009-08-06 | 2015-04-07 | Duoject Medical Systems Inc. | Airless mixing with a by-pass syringe |
KR100981244B1 (en) | 2010-03-18 | 2010-09-10 | 신동하 | Improved disposable syringe |
IL206024A0 (en) * | 2010-05-27 | 2010-11-30 | Red Sea Fish Pharm Ltd | Handheld titration device |
JP5996544B2 (en) | 2010-10-15 | 2016-09-21 | クリアサイド・バイオメディカル・インコーポレーテッドClearside Biomedical Incorporated | Eye access device |
CN103501751B (en) * | 2011-03-04 | 2016-11-23 | 杜杰克特医疗系统有限公司 | The transmission system easily coupled |
KR20140138336A (en) | 2012-05-30 | 2014-12-03 | 미쓰이 가가쿠 가부시키가이샤 | Three-component mixing apparatus and three-component mixing adhesive kit |
US9724269B2 (en) | 2012-11-30 | 2017-08-08 | Becton Dickinson and Company Ltd. | Connector for fluid communication |
US9486573B2 (en) | 2013-03-14 | 2016-11-08 | Bayer Healthcare Llc | Fluid delivery system and method of fluid delivery to a patient |
US10022301B2 (en) | 2013-03-15 | 2018-07-17 | Becton Dickinson and Company Ltd. | Connection system for medical device components |
EP4378444A3 (en) | 2013-05-03 | 2024-07-03 | Clearside Biomedical, Inc. | Apparatus and methods for ocular injection |
EP3527190A1 (en) | 2013-07-17 | 2019-08-21 | Bayer Healthcare, LLC | Cartridge-based in-bore infuser |
US10918790B2 (en) * | 2015-12-22 | 2021-02-16 | Guangzhou Bioseal Biotech Co., Ltd. | Dual syringe with funnel feeding kit |
WO2019084371A1 (en) * | 2017-10-26 | 2019-05-02 | Cook Regentec Llc | Adaptor for vials and syringes |
WO2021037502A1 (en) * | 2019-08-23 | 2021-03-04 | Zealand Pharma A/S | Adapter for a fluid transfer device |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2326490A (en) * | 1942-06-13 | 1943-08-10 | Harold N Perelson | Fluid dispenser |
US3826260A (en) * | 1971-12-27 | 1974-07-30 | Upjohn Co | Vial and syringe combination |
US3872867A (en) * | 1971-06-02 | 1975-03-25 | Upjohn Co | Wet-dry additive assembly |
US3938518A (en) * | 1975-01-15 | 1976-02-17 | Astra Pharmaceutical Products Inc. | Syringe attachment device |
US3940003A (en) * | 1974-05-07 | 1976-02-24 | Pharmaco, Inc. | Safety cap for medicament vial having puncturable seal |
US3977555A (en) * | 1974-05-07 | 1976-08-31 | Pharmaco, Inc. | Protective safety cap for medicament vial |
US4439184A (en) * | 1982-05-03 | 1984-03-27 | Concord Laboratories, Inc. | Two-dose syringe |
US4516967A (en) * | 1981-12-21 | 1985-05-14 | Kopfer Rudolph J | Wet-dry compartmental syringe |
US4834152A (en) * | 1986-02-27 | 1989-05-30 | Intelligent Medicine, Inc. | Storage receptacle sealing and transfer apparatus |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3563373A (en) * | 1967-10-06 | 1971-02-16 | Paul E Paulson | Hypodermic syringe assembly |
DE1913626A1 (en) * | 1969-03-18 | 1970-10-01 | Friedrich Gebhard | Rotary piston engine |
DE1913926A1 (en) * | 1969-03-19 | 1970-09-24 | Hoechst Ag | Two-chamber syringe |
US4060082A (en) * | 1976-08-16 | 1977-11-29 | Mpl, Inc. | Dual-ingredient medication dispenser |
ATE27907T1 (en) * | 1982-10-27 | 1987-07-15 | Duphar Int Res | INJECTION SYRINGE WITH TELESCOPIC CONNECTION BETWEEN SYRINGE BODY AND MEDICATION CONTAINER. |
US4583971A (en) * | 1984-02-10 | 1986-04-22 | Travenol European Research And Development Centre (Teradec) | Closed drug delivery system |
US4675020A (en) * | 1985-10-09 | 1987-06-23 | Kendall Mcgaw Laboratories, Inc. | Connector |
US4886495A (en) * | 1987-07-08 | 1989-12-12 | Duoject Medical Systems Inc. | Vial-based prefilled syringe system for one or two component medicaments |
US5554125A (en) * | 1987-07-08 | 1996-09-10 | Reynolds; David L. | Prefilled vial syringe |
US5364369A (en) * | 1987-07-08 | 1994-11-15 | Reynolds David L | Syringe |
JPH021277A (en) * | 1988-03-31 | 1990-01-05 | Fujisawa Pharmaceut Co Ltd | Infusion container |
US4898209A (en) * | 1988-09-27 | 1990-02-06 | Baxter International Inc. | Sliding reconstitution device with seal |
US5171214A (en) * | 1990-12-26 | 1992-12-15 | Abbott Laboratories | Drug storage and delivery system |
US5075057A (en) * | 1991-01-08 | 1991-12-24 | Hoedl Herbert K | Manufacture of molded composite products from scrap plastics |
JPH06508528A (en) * | 1992-03-23 | 1994-09-29 | ネクセル セラピューティクス インコーポレーテッド | In vitro derived human neutrophil precursor cells |
US5827262A (en) * | 1993-09-07 | 1998-10-27 | Debiotech S.A. | Syringe device for mixing two compounds |
US5472022A (en) * | 1993-11-02 | 1995-12-05 | Genentech, Inc. | Injection pen solution transfer apparatus and method |
FR2726768A1 (en) * | 1994-11-14 | 1996-05-15 | Debiotech Sa | SYRINGE DEVICE ATTACHABLE TO A VIAL |
AU7617296A (en) * | 1995-12-06 | 1997-06-27 | Gabriel Meyer | Device for preparing a medicinal solution reconstituted from two components |
-
1997
- 1997-01-10 JP JP52469597A patent/JP4187790B2/en not_active Expired - Fee Related
- 1997-01-10 AU AU13626/97A patent/AU726244B2/en not_active Ceased
- 1997-01-10 DK DK97900167T patent/DK0928182T3/en active
- 1997-01-10 CA CA002242915A patent/CA2242915C/en not_active Expired - Fee Related
- 1997-01-10 DE DE69712499T patent/DE69712499T2/en not_active Expired - Lifetime
- 1997-01-10 PT PT97900167T patent/PT928182E/en unknown
- 1997-01-10 WO PCT/CA1997/000017 patent/WO1997025015A1/en active IP Right Grant
- 1997-01-10 AT AT97900167T patent/ATE217181T1/en not_active IP Right Cessation
- 1997-01-10 ES ES97900167T patent/ES2176661T3/en not_active Expired - Lifetime
- 1997-01-10 EP EP19970900167 patent/EP0928182B1/en not_active Expired - Lifetime
-
1998
- 1998-07-13 US US09/114,063 patent/US6149623A/en not_active Expired - Lifetime
-
2000
- 2000-09-25 US US09/668,159 patent/US6638244B1/en not_active Expired - Lifetime
-
2003
- 2003-02-14 US US10/367,607 patent/US20040024354A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2326490A (en) * | 1942-06-13 | 1943-08-10 | Harold N Perelson | Fluid dispenser |
US3872867A (en) * | 1971-06-02 | 1975-03-25 | Upjohn Co | Wet-dry additive assembly |
US3826260A (en) * | 1971-12-27 | 1974-07-30 | Upjohn Co | Vial and syringe combination |
US3940003A (en) * | 1974-05-07 | 1976-02-24 | Pharmaco, Inc. | Safety cap for medicament vial having puncturable seal |
US3977555A (en) * | 1974-05-07 | 1976-08-31 | Pharmaco, Inc. | Protective safety cap for medicament vial |
US3938518A (en) * | 1975-01-15 | 1976-02-17 | Astra Pharmaceutical Products Inc. | Syringe attachment device |
US4516967A (en) * | 1981-12-21 | 1985-05-14 | Kopfer Rudolph J | Wet-dry compartmental syringe |
US4439184A (en) * | 1982-05-03 | 1984-03-27 | Concord Laboratories, Inc. | Two-dose syringe |
US4834152A (en) * | 1986-02-27 | 1989-05-30 | Intelligent Medicine, Inc. | Storage receptacle sealing and transfer apparatus |
Cited By (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11224730B2 (en) | 2003-10-30 | 2022-01-18 | Simplivia Healthcare Ltd. | Safely drug handling device |
US10953216B2 (en) | 2003-10-30 | 2021-03-23 | Simplivia Healtcare Ltd. | Safety drug handling device |
US20060200095A1 (en) * | 2005-03-02 | 2006-09-07 | Steube Gregory A | Blunt tip vial access cannula |
US8540686B2 (en) | 2005-03-02 | 2013-09-24 | Covidien Ag | Blunt tip vial access cannula |
US20080215030A1 (en) * | 2005-08-08 | 2008-09-04 | Eli Lilly And Company | Assembly for Filling a Container of a Delivery Device with a Pharmaceutical |
US20100036319A1 (en) * | 2007-02-01 | 2010-02-11 | Pa Knowledge Limited | Auto injector |
US8435210B2 (en) | 2007-04-17 | 2013-05-07 | Medimop Medical Projects Ltd. | Fluid control device with manually depressed actuator |
US8317743B2 (en) | 2007-09-18 | 2012-11-27 | Medimop Medical Projects Ltd. | Medicament mixing and injection apparatus |
US7981089B2 (en) | 2008-03-31 | 2011-07-19 | Tyco Healthcare Group Lp | Vial access device |
US20090247962A1 (en) * | 2008-03-31 | 2009-10-01 | Tyco Healthcare Group Lp | Vial Access Device |
US8821436B2 (en) | 2008-04-01 | 2014-09-02 | Yukon Medical, Llc | Dual container fluid transfer device |
US20110087164A1 (en) * | 2008-04-01 | 2011-04-14 | Yukon Medical, Llc | Dual container fluid transfer device |
US9713573B2 (en) | 2008-06-30 | 2017-07-25 | Covidien Lp | Blunt tip vial access cannula and method for manufacture |
US8382722B2 (en) | 2008-06-30 | 2013-02-26 | Covidien Lp | Blunt tip vial access cannula and method for manufacture |
US20090326485A1 (en) * | 2008-06-30 | 2009-12-31 | Carlyon James L | Blunt tip vial access cannula and method for manufacture |
US8998875B2 (en) | 2009-10-01 | 2015-04-07 | Medimop Medical Projects Ltd. | Vial assemblage with vial and pre-attached fluid transfer device |
US20110106045A1 (en) * | 2009-10-30 | 2011-05-05 | Reynolds David L | Inter vial transfer system |
AU2010312289B2 (en) * | 2009-10-30 | 2015-04-23 | Duoject Medical Systems Inc. | Inter vial transfer system |
CN102639183A (en) * | 2009-10-30 | 2012-08-15 | 雷文斯治疗公司 | Device and method for topical application of therapeutics or cosmetic compositions |
CN102596145A (en) * | 2009-10-30 | 2012-07-18 | 杜杰克特医疗系统有限公司 | Inter vial transfer system |
US20110106021A1 (en) * | 2009-10-30 | 2011-05-05 | Revance Therapeutics, Inc. | Device and Method for Topical Application of Therapeutics or Cosmetic Compositions |
US8915902B2 (en) * | 2009-10-30 | 2014-12-23 | Duoject Medical Systems Inc. | Inter vial transfer system |
US9132063B2 (en) | 2009-11-12 | 2015-09-15 | Medimop Medical Projects Ltd. | Inline liquid drug medical devices with linear displaceable sliding flow control member |
US8608723B2 (en) | 2009-11-12 | 2013-12-17 | Medimop Medical Projects Ltd. | Fluid transfer devices with sealing arrangement |
US8979792B2 (en) | 2009-11-12 | 2015-03-17 | Medimop Medical Projects Ltd. | Inline liquid drug medical devices with linear displaceable sliding flow control member |
US8753325B2 (en) | 2010-02-24 | 2014-06-17 | Medimop Medical Projects, Ltd. | Liquid drug transfer device with vented vial adapter |
US8684994B2 (en) | 2010-02-24 | 2014-04-01 | Medimop Medical Projects Ltd. | Fluid transfer assembly with venting arrangement |
USD655017S1 (en) | 2010-06-17 | 2012-02-28 | Yukon Medical, Llc | Shroud |
USD669980S1 (en) | 2010-10-15 | 2012-10-30 | Medimop Medical Projects Ltd. | Vented vial adapter |
US8852145B2 (en) | 2010-11-14 | 2014-10-07 | Medimop Medical Projects, Ltd. | Inline liquid drug medical device having rotary flow control member |
WO2012063230A1 (en) * | 2010-11-14 | 2012-05-18 | Medimop Medical Projects Ltd | Inline liquid drug medical device having rotary flow control member |
US8752598B2 (en) | 2011-04-17 | 2014-06-17 | Medimop Medical Projects Ltd. | Liquid drug transfer assembly |
USD681230S1 (en) | 2011-09-08 | 2013-04-30 | Yukon Medical, Llc | Shroud |
US9125992B2 (en) | 2011-09-16 | 2015-09-08 | Melvin A. Finke | Fluid delivery device with filtration |
US8905994B1 (en) | 2011-10-11 | 2014-12-09 | Medimop Medical Projects, Ltd. | Valve assembly for use with liquid container and drug vial |
USD674088S1 (en) | 2012-02-13 | 2013-01-08 | Medimop Medical Projects Ltd. | Vial adapter |
USD737436S1 (en) | 2012-02-13 | 2015-08-25 | Medimop Medical Projects Ltd. | Liquid drug reconstitution assembly |
USD720451S1 (en) | 2012-02-13 | 2014-12-30 | Medimop Medical Projects Ltd. | Liquid drug transfer assembly |
CN104159626A (en) * | 2012-03-08 | 2014-11-19 | 贝克顿·迪金森公司 | Drug reconstitution system |
US20160015900A1 (en) * | 2012-03-08 | 2016-01-21 | Becton, Dickinson And Company | Drug Reconstitution System |
US11833110B2 (en) | 2012-03-08 | 2023-12-05 | Becton, Dickinson And Company | Drug reconstitution system |
US10888497B2 (en) * | 2012-03-08 | 2021-01-12 | Becton, Dickinson And Company | Drug reconstitution system |
US20180200449A1 (en) * | 2012-03-08 | 2018-07-19 | Becton, Dickinson And Company | Drug Reconstitution System |
CN106237450A (en) * | 2012-03-08 | 2016-12-21 | 贝克顿·迪金森公司 | Drug reconstitution system |
US9950119B2 (en) * | 2012-03-08 | 2018-04-24 | Becton, Dickinson And Company | Drug reconstitution system |
US9283324B2 (en) | 2012-04-05 | 2016-03-15 | Medimop Medical Projects, Ltd | Fluid transfer devices having cartridge port with cartridge ejection arrangement |
USD769444S1 (en) | 2012-06-28 | 2016-10-18 | Yukon Medical, Llc | Adapter device |
US9795536B2 (en) | 2012-08-26 | 2017-10-24 | Medimop Medical Projects, Ltd. | Liquid drug transfer devices employing manual rotation for dual flow communication step actuations |
US9839580B2 (en) | 2012-08-26 | 2017-12-12 | Medimop Medical Projects, Ltd. | Liquid drug transfer devices |
US10299990B2 (en) | 2012-08-26 | 2019-05-28 | West Pharma. Services IL, Ltd. | Liquid drug transfer devices |
US9339438B2 (en) | 2012-09-13 | 2016-05-17 | Medimop Medical Projects Ltd. | Telescopic female drug vial adapter |
USD734868S1 (en) | 2012-11-27 | 2015-07-21 | Medimop Medical Projects Ltd. | Drug vial adapter with downwardly depending stopper |
US9801786B2 (en) | 2013-04-14 | 2017-10-31 | Medimop Medical Projects Ltd. | Drug container closure for mounting on open-topped drug container to form drug reconstitution assemblage for use with needleless syringe |
US9943463B2 (en) | 2013-05-10 | 2018-04-17 | West Pharma. Services IL, Ltd. | Medical devices including vial adapter with inline dry drug module |
USD765837S1 (en) | 2013-08-07 | 2016-09-06 | Medimop Medical Projects Ltd. | Liquid transfer device with integral vial adapter |
USD767124S1 (en) | 2013-08-07 | 2016-09-20 | Medimop Medical Projects Ltd. | Liquid transfer device with integral vial adapter |
US10688295B2 (en) | 2013-08-07 | 2020-06-23 | West Pharma. Services IL, Ltd. | Liquid transfer devices for use with infusion liquid containers |
USD757933S1 (en) | 2014-09-11 | 2016-05-31 | Medimop Medical Projects Ltd. | Dual vial adapter assemblage |
US20170304525A1 (en) * | 2014-10-08 | 2017-10-26 | Vetter Pharma-Fertigung GmbH & Co. KG | System and method for providing an injection |
US10285907B2 (en) | 2015-01-05 | 2019-05-14 | West Pharma. Services IL, Ltd. | Dual vial adapter assemblages with quick release drug vial adapter for ensuring correct usage |
US10391233B2 (en) * | 2015-04-20 | 2019-08-27 | Tgel Bio Co., Ltd. | Drug delivery kit, and apparatus and method for preparing drug delivery system |
US10357429B2 (en) | 2015-07-16 | 2019-07-23 | West Pharma. Services IL, Ltd. | Liquid drug transfer devices for secure telescopic snap fit on injection vials |
USD801522S1 (en) | 2015-11-09 | 2017-10-31 | Medimop Medical Projects Ltd. | Fluid transfer assembly |
US10278897B2 (en) | 2015-11-25 | 2019-05-07 | West Pharma. Services IL, Ltd. | Dual vial adapter assemblage including drug vial adapter with self-sealing access valve |
WO2017125920A1 (en) * | 2016-01-21 | 2017-07-27 | Teva Medical Ltd. | Luer lock adaptor |
US10682505B2 (en) | 2016-01-21 | 2020-06-16 | Simplivia Healthcare Ltd. | Luer lock adaptor |
US11517731B2 (en) | 2016-01-21 | 2022-12-06 | Simplivia Healthcare Ltd. | Luer lock adaptor |
US10022531B2 (en) | 2016-01-21 | 2018-07-17 | Teva Medical Ltd. | Luer lock adaptor |
US10765604B2 (en) | 2016-05-24 | 2020-09-08 | West Pharma. Services IL, Ltd. | Drug vial adapter assemblages including vented drug vial adapter and vented liquid vial adapter |
US10646404B2 (en) | 2016-05-24 | 2020-05-12 | West Pharma. Services IL, Ltd. | Dual vial adapter assemblages including identical twin vial adapters |
US10806667B2 (en) | 2016-06-06 | 2020-10-20 | West Pharma. Services IL, Ltd. | Fluid transfer devices for filling drug pump cartridges with liquid drug contents |
US10806671B2 (en) | 2016-08-21 | 2020-10-20 | West Pharma. Services IL, Ltd. | Syringe assembly |
USD832430S1 (en) | 2016-11-15 | 2018-10-30 | West Pharma. Services IL, Ltd. | Dual vial adapter assemblage |
US10772798B2 (en) | 2016-12-06 | 2020-09-15 | West Pharma Services Il, Ltd. | Liquid transfer device with integral telescopic vial adapter for use with infusion liquid container and discrete injection vial |
US11786443B2 (en) | 2016-12-06 | 2023-10-17 | West Pharma. Services IL, Ltd. | Liquid transfer device with integral telescopic vial adapter for use with infusion liquid container and discrete injection vial |
US10772797B2 (en) | 2016-12-06 | 2020-09-15 | West Pharma. Services IL, Ltd. | Liquid drug transfer devices for use with intact discrete injection vial release tool |
US10945921B2 (en) | 2017-03-29 | 2021-03-16 | West Pharma. Services IL, Ltd. | User actuated liquid drug transfer devices for use in ready-to-use (RTU) liquid drug transfer assemblages |
US11554215B2 (en) | 2017-06-08 | 2023-01-17 | Novartis Ag | Injection device and injection solution transferring system |
US11642285B2 (en) | 2017-09-29 | 2023-05-09 | West Pharma. Services IL, Ltd. | Dual vial adapter assemblages including twin vented female vial adapters |
WO2019152589A1 (en) * | 2018-02-02 | 2019-08-08 | Becton, Dickinson And Company | Syringe assembly |
CN111867546A (en) * | 2018-03-20 | 2020-10-30 | 贝克顿迪金森有限公司 | Connection arrangement for closed system transfer of fluids |
US11413216B2 (en) * | 2018-03-20 | 2022-08-16 | Becton Dickinson and Company Limited | Connection arrangement for closed system transfer of fluids |
USD903864S1 (en) | 2018-06-20 | 2020-12-01 | West Pharma. Services IL, Ltd. | Medication mixing apparatus |
USD917693S1 (en) | 2018-07-06 | 2021-04-27 | West Pharma. Services IL, Ltd. | Medication mixing apparatus |
USD923812S1 (en) | 2019-01-16 | 2021-06-29 | West Pharma. Services IL, Ltd. | Medication mixing apparatus |
USD923782S1 (en) | 2019-01-17 | 2021-06-29 | West Pharma. Services IL, Ltd. | Medication mixing apparatus |
US11918542B2 (en) | 2019-01-31 | 2024-03-05 | West Pharma. Services IL, Ltd. | Liquid transfer device |
US11484470B2 (en) | 2019-04-30 | 2022-11-01 | West Pharma. Services IL, Ltd. | Liquid transfer device with dual lumen IV spike |
USD954253S1 (en) | 2019-04-30 | 2022-06-07 | West Pharma. Services IL, Ltd. | Liquid transfer device |
US11786442B2 (en) | 2019-04-30 | 2023-10-17 | West Pharma. Services IL, Ltd. | Liquid transfer device with dual lumen IV spike |
USD956958S1 (en) | 2020-07-13 | 2022-07-05 | West Pharma. Services IL, Ltd. | Liquid transfer device |
WO2023081145A1 (en) * | 2021-11-03 | 2023-05-11 | Merck Sharp & Dohme Llc | Vial-to-syringe converter and methods of making and using same |
USD1043974S1 (en) | 2022-04-22 | 2024-09-24 | West Pharma. Services IL, Ltd. | Liquid transfer device |
Also Published As
Publication number | Publication date |
---|---|
AU1362697A (en) | 1997-08-01 |
CA2242915C (en) | 2001-08-21 |
ATE217181T1 (en) | 2002-05-15 |
DE69712499D1 (en) | 2002-06-13 |
ES2176661T3 (en) | 2002-12-01 |
US6638244B1 (en) | 2003-10-28 |
WO1997025015A1 (en) | 1997-07-17 |
DE69712499T2 (en) | 2002-11-14 |
EP0928182A1 (en) | 1999-07-14 |
DK0928182T3 (en) | 2002-08-26 |
JPH11510087A (en) | 1999-09-07 |
JP4187790B2 (en) | 2008-11-26 |
PT928182E (en) | 2002-10-31 |
US6149623A (en) | 2000-11-21 |
AU726244B2 (en) | 2000-11-02 |
CA2242915A1 (en) | 1997-07-17 |
EP0928182B1 (en) | 2002-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040024354A1 (en) | Transfer device and method for transferring a pharmaceutical component between a vial and a syringe | |
US7736353B2 (en) | Pharmaceutical delivery systems and methods for using same | |
US4568346A (en) | Hypodermic syringe having a telescopic assembly between cartridge and medicament holder | |
CA2568184C (en) | Reconstituting device for injectable medication | |
CA2221434C (en) | Syringe filling and delivery device | |
US7470257B2 (en) | Syringe safety device | |
US20060155257A1 (en) | Pharmaceutical delivery systems and methods for using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |